Retinoic	O
acid-induced	O
expression	O
of	O
CD38	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
retinoic	B-protein
acid	I-protein
receptor-alpha	I-protein
.	O

CD38	B-protein
is	O
a	O
leukocyte	B-protein
differentiation	I-protein
antigen	I-protein
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T-	B-cell_type
and	I-cell_type
B-	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
myeloid	B-cell_type
cells	I-cell_type
,	O
CD38	B-protein
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

Virtually	O
no	O
information	O
is	O
available	O
on	O
regulation	O
and	O
functions	O
of	O
CD38	B-protein
.	O

Recently	O
we	O
reported	O
that	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
a	O
potent	O
and	O
highly	O
specific	O
inducer	O
of	O
CD38	B-protein
expression	O
in	O
human	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Here	O
we	O
report	O
that	O
ATRA-induced	O
expression	O
of	O
CD38	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
retinoic	B-protein
acid-alpha	I-protein
receptor	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O

ATRA	O
failed	O
to	O
induce	O
CD38	B-protein
expression	O
in	O
a	O
mutant	B-cell_line
subclone	I-cell_line
of	O
the	O
HL-60	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
designated	O
HL-60R	B-cell_line
)	O
that	O
is	O
relatively	O
resistant	O
to	O
ATRA-induced	O
granulocytic	O
differentiation	O
.	O

Retroviral	O
vector-mediated	O
transduction	O
of	O
RA	B-protein
receptor	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
into	O
this	O
HL-60R	B-cell_line
subclone	I-cell_line
completely	O
restored	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
ATRA	O
in	O
terms	O
of	O
their	O
ability	O
to	O
express	O
CD38	B-protein
.	O

In	O
contrast	O
,	O
CD38	B-protein
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL-60R	B-cell_line
cells	I-cell_line
,	O
transfected	O
with	O
a	O
functional	O
RAR	B-protein
beta	I-protein
,	O
RAR	B-protein
gamma	I-protein
,	O
or	O
RXR	B-protein
alpha	I-protein
receptor	I-protein
.	O

Induction	O
of	O
CD38	B-protein
in	O
acute	B-cell_type
promyelocytic	I-cell_type
and	I-cell_type
acute	I-cell_type
myeloblastic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
was	O
independent	O
of	O
ATRA-induced	O
cytodifferentiation	O
.	O

Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	B-protein
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
on	O
normal	B-cell_type
circulating	I-cell_type
granulocytes	I-cell_type
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CD38	B-protein
is	O
ATRA	O
inducible	O
in	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O

This	O
effect	O
is	O
independent	O
of	O
differentiation	O
and	O
is	O
mediated	O
by	O
RAR	B-protein
alpha	I-protein
in	O
HL-60	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
similar	O
role	O
for	O
RAR	B-protein
alpha	I-protein
in	O
CD38	B-protein
expression	O
in	O
other	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
54	NULL
,	NULL
1746-1752	NULL
,	NULL
April	NULL
1	NULL
,	NULL
1994	NULL
]	NULL
Retinoic	NULL
Acid-induced	NULL
Expression	NULL
of	NULL
CD38	NULL
Antigen	NULL
in	NULL
Myeloid	NULL
Cells	NULL
Is	NULL
Mediated	NULL
through	NULL
Retinoic	NULL
Acid	NULL
Receptor-a	NULL
«	NULL
'	NULL
Johannes	NULL
Drach	NULL
,	NULL
Teresa	NULL
McQueen	NULL
,	NULL
Heike	NULL
Engel	NULL
,	NULL
Michael	NULL
Andreeff	NULL
,	NULL
Kent	NULL
A.	NULL
Robertson	NULL
,	NULL
Steven	NULL
J.	NULL
Collins	NULL
,	NULL
Fabio	NULL
Malavasi	NULL
,	NULL
and	NULL
Kapil	NULL
Mehta*	NULL
Department	NULL
of	NULL
Hematology	NULL
[	NULL
J.	NULL
D.	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
M	NULL
.	NULL

A	NULL
.	NULL
]	NULL

and	NULL
Clinical	NULL
Investigations	NULL
[	NULL
T.	NULL
M.	NULL
,	NULL
K.	NULL
M.	NULL
]	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Houston	NULL
,	NULL
Texas	NULL
77030	NULL
;	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98125	NULL
[	NULL
K.	NULL
A.	NULL
R.	NULL
,	NULL
S.	NULL
J.	NULL
C.	NULL
]	NULL
;	NULL
and	NULL
Laboratory	NULL
of	NULL
Cell	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
Torino	NULL
,	NULL
Torino	NULL
,	NULL
Italy	NULL
[	NULL
F.	NULL
M.	NULL
]	NULL
ABSTRACT	NULL
CD38	NULL
is	NULL
a	NULL
leukocyte	NULL
differentiation	NULL
antigen	NULL
that	NULL
has	NULL
been	NULL
thought	NULL
to	NULL
be	NULL
a	NULL
phenotypic	NULL
marker	NULL
of	NULL
different	NULL
subpopulations	NULL
of	NULL
T-and	NULL
B-lymphocytes	NULL
.	NULL

In	NULL
myeloid	NULL
cells	NULL
,	NULL
CD38	NULL
is	NULL
expressed	NULL
during	NULL
early	NULL
stages	NULL
of	NULL
differentiation	NULL
.	NULL

Virtually	NULL
no	NULL
information	NULL
is	NULL
available	NULL
on	NULL
regulation	NULL
and	NULL
functions	NULL
of	NULL
CD38	NULL
.	NULL

Recently	NULL
we	NULL
reported	NULL
that	NULL
all-frans-retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
is	NULL
a	NULL
potent	NULL
and	NULL
highly	NULL
specific	NULL
inducer	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
ATRA-induced	NULL
expression	NULL
of	NULL
CD38	NULL
antigen	NULL
in	NULL
myeloid	NULL
cells	NULL
is	NULL
mediated	NULL
through	NULL
retinoic	NULL
acid-	NULL
receptor	NULL
(	NULL
RARa	NULL
)	NULL
.	NULL

ATRA	NULL
failed	NULL
to	NULL
induce	NULL
CD38	NULL
expression	NULL
in	NULL
a	NULL
mutant	NULL
subclone	NULL
of	NULL
the	NULL
HL-60	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
designated	NULL
HL-60R	NULL
)	NULL
that	NULL
is	NULL
relatively	NULL
resistant	NULL
to	NULL
ATRA-induced	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

Retroviral	NULL
vector-mediated	NULL
transduction	NULL
of	NULL
RA	NULL
receptor	NULL
(	NULL
RARa	NULL
)	NULL
into	NULL
this	NULL
HL-6OR	NULL
subclone	NULL
completely	NULL
restored	NULL
the	NULL
sensitivity	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
ATRA	NULL
in	NULL
terms	NULL
of	NULL
their	NULL
ability	NULL
to	NULL
express	NULL
CD38	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CD38	NULL
expression	NULL
was	NULL
not	NULL
inducible	NULL
by	NULL
ATRA	NULL
in	NULL
HL-6OR	NULL
cells	NULL
,	NULL
transfected	NULL
with	NULL
a	NULL
functional	NULL
RARB	NULL
,	NULL
RAR+y	NULL
,	NULL
or	NULL
RXRa	NULL
receptor	NULL
.	NULL

Induction	NULL
of	NULL
CD38	NULL
in	NULL
acute	NULL
promyelocytic	NULL
and	NULL
acute	NULL
myeloblastic	NULL
leukemia	NULL
cells	NULL
was	NULL
independent	NULL
of	NULL
ATRA-induced	NULL
cytodifferentiation	NULL
.	NULL

Following	NULL
culture	NULL
with	NULL
ATRA	NULL
,	NULL
increased	NULL
CD38	NULL
protein	NULL
levels	NULL
were	NULL
also	NULL
observed	NULL
in	NULL
normal	NULL
CD34*	NULL
bone	NULL
marrow	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
on	NULL
normal	NULL
circulating	NULL
granulocytes	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
CD38	NULL
is	NULL
ATRA	NULL
inducible	NULL
in	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
and	NULL
normal	NULL
CD34*	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

This	NULL
effect	NULL
is	NULL
independent	NULL
of	NULL
differentiation	NULL
and	NULL
is	NULL
mediated	NULL
by	NULL
RARa	NULL
in	NULL
HL-60	NULL
cells	NULL
,	NULL
suggesting	NULL
a	NULL
similar	NULL
role	NULL
for	NULL
RARa	NULL
in	NULL
CD38	NULL
expression	NULL
in	NULL
other	NULL
hematopoietic	NULL
cells	NULL
.	NULL

INTRODUCTION	NULL
One	NULL
of	NULL
the	NULL
earliest	NULL
characterized	NULL
but	NULL
perhaps	NULL
least	NULL
studied	NULL
lymphocyte	NULL
differentiation	NULL
antigens	NULL
is	NULL
the	NULL
CD38	NULL
,	NULL
a	NULL
membrane	NULL
glycoprotein	NULL
of	NULL
M	NULL
,	NULL
46,000	NULL
.	NULL

CD38	NULL
has	NULL
a	NULL
rather	NULL
unique	NULL
pattern	NULL
of	NULL
expression	NULL
and	NULL
is	NULL
expressed	NULL
during	NULL
early	NULL
or	NULL
late	NULL
,	NULL
but	NULL
not	NULL
intermediate	NULL
,	NULL
stages	NULL
of	NULL
T-	NULL
and	NULL
B-cell	NULL
differentiation	NULL
(	NULL
1-6	NULL
)	NULL
.	NULL

Within	NULL
the	NULL
myeloid	NULL
lineage	NULL
,	NULL
CD38	NULL
is	NULL
mainly	NULL
expressed	NULL
by	NULL
precursor	NULL
cells	NULL
,	NULL
and	NULL
only	NULL
weak	NULL
expression	NULL
has	NULL
been	NULL
observed	NULL
on	NULL
mature	NULL
myeloid	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Its	NULL
expression	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
on	NULL
the	NULL
malignant	NULL
counterparts	NULL
of	NULL
these	NULL
hematopoietic	NULL
cells	NULL
,	NULL
and	NULL
CD38	NULL
may	NULL
be	NULL
of	NULL
prognostic	NULL
relevance	NULL
in	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
(	NULL
9	NULL
)	NULL
.	NULL

However	NULL
,	NULL
virtually	NULL
no	NULL
information	NULL
is	NULL
available	NULL
on	NULL
the	NULL
regulation	NULL
and	NULL
function	NULL
of	NULL
CD38	NULL
in	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
.	NULL

The	NULL
retinoids	NULL
(	NULL
natural	NULL
and	NULL
synthetic	NULL
analogues	NULL
of	NULL
vitamin	NULL
A	NULL
)	NULL
,	NULL
particularly	NULL
retinoic	NULL
acid	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
exert	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
biological	NULL
effects	NULL
.	NULL

For	NULL
example	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
a	NULL
possible	NULL
morphogen	NULL
in	NULL
the	NULL
embryonic	NULL
tissues	NULL
of	NULL
frogs	NULL
and	NULL
chickens	NULL
,	NULL
an	NULL
effective	NULL
agent	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
certain	NULL
dermatological	NULL
disorders	NULL
,	NULL
an	NULL
immunomodulator	NULL
,	NULL
and	NULL
an	NULL
important	NULL
regulator	NULL
of	NULL
the	NULL
cell	NULL
growth	NULL
and	NULL
Received	NULL
8/17/93	NULL
;	NULL
accepted	NULL
1/28/94	NULL
.	NULL

The	NULL
cost	NULL
of	NULL
publication	NULL
of	NULL
the	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
Argus	NULL
Pharmaceuticals	NULL
,	NULL
Inc.	NULL
,	NULL
The	NULL
Woodlands	NULL
,	NULL
TX	NULL
,	NULL
and	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Food	NULL
and	NULL
Drug	NULL
Administration	NULL
(	NULL
FD-R-000923	NULL
)	NULL
,	NULL
from	NULL
NIH	NULL
(	NULL
CA	NULL
55397	NULL
,	NULL
CA	NULL
57369	NULL
,	NULL
CA	NULL
16672	NULL
,	NULL
and	NULL
CA	NULL
55164	NULL
)	NULL
,	NULL
European	NULL
Economic	NULL
Community	NULL
Biotechnology	NULL
Project	NULL
(	NULL
Brussels	NULL
,	NULL
Belgium	NULL
,	NULL
BI0O2/CT92/0269	NULL
)	NULL
,	NULL
and	NULL
Target	NULL
Project	NULL
``	NULL
Appli-cazioni	NULL
Cliniche	NULL
Ricerca	NULL
Oncologica	NULL
``	NULL
(	NULL
Consiglio	NULL
Nazionale	NULL
Ricerche	NULL
,	NULL
Rome	NULL
,	NULL
Italy	NULL
)	NULL
.	NULL

K.	NULL
A.	NULL
R.	NULL
is	NULL
a	NULL
special	NULL
fellow	NULL
of	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

2	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Department	NULL
of	NULL
Clinical	NULL
Investigations	NULL
,	NULL
Box	NULL
60	NULL
,	NULL
1515	NULL
Holcombe	NULL
Boulevard	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
77030.	NULL
differentiation	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
(	NULL
10-14	NULL
)	NULL
.	NULL

ATRA	NULL
is	NULL
a	NULL
powerful	NULL
inducer	NULL
of	NULL
differentiation	NULL
in	NULL
APL	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

When	NULL
administered	NULL
as	NULL
a	NULL
single	NULL
agent	NULL
,	NULL
ATRA	NULL
induces	NULL
complete	NULL
clinical	NULL
remissions	NULL
in	NULL
a	NULL
majority	NULL
of	NULL
patients	NULL
with	NULL
APL	NULL
(	NULL
16-18	NULL
)	NULL
.	NULL

These	NULL
and	NULL
other	NULL
biological	NULL
effects	NULL
of	NULL
retinoids	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
primarily	NULL
mediated	NULL
through	NULL
specific	NULL
receptors	NULL
that	NULL
are	NULL
members	NULL
of	NULL
the	NULL
steroid-thyroid	NULL
hormone	NULL
receptor	NULL
superfamily	NULL
of	NULL
nuclear	NULL
transcription	NULL
factors	NULL
.	NULL

To	NULL
date	NULL
,	NULL
several	NULL
human	NULL
retinoic	NULL
receptors	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
including	NULL
RARa	NULL
,	NULL
which	NULL
is	NULL
widely	NULL
expressed	NULL
in	NULL
different	NULL
hematopoietic	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
;	NULL
RAR	NULL
$	NULL
,	NULL
which	NULL
is	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
epithelial	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
;	NULL
and	NULL
RARy	NULL
,	NULL
which	NULL
is	NULL
predominantly	NULL
expressed	NULL
in	NULL
the	NULL
skin	NULL
tissue	NULL
(	NULL
21	NULL
)	NULL
.	NULL

RXRa	NULL
is	NULL
another	NULL
retinoic	NULL
acid	NULL
receptor	NULL
that	NULL
has	NULL
been	NULL
identified	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
differ	NULL
from	NULL
RARs	NULL
in	NULL
primary	NULL
sequence	NULL
and	NULL
in	NULL
its	NULL
pharmacological	NULL
response	NULL
to	NULL
retinoids	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Interaction	NULL
of	NULL
retinoid	NULL
with	NULL
a	NULL
specific	NULL
receptor	NULL
permits	NULL
binding	NULL
of	NULL
the	NULL
receptor	NULL
to	NULL
specific	NULL
cis-acting	NULL
DNA	NULL
sequences	NULL
which	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
induces	NULL
or	NULL
suppresses	NULL
the	NULL
transcription	NULL
of	NULL
certain	NULL
target	NULL
genes	NULL
.	NULL

Since	NULL
different	NULL
isoforms	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
exhibit	NULL
distinct	NULL
patterns	NULL
of	NULL
tissue-specific	NULL
expression	NULL
,	NULL
they	NULL
might	NULL
mediate	NULL
distinct	NULL
biological	NULL
activities	NULL
.	NULL

However	NULL
,	NULL
to	NULL
date	NULL
there	NULL
have	NULL
been	NULL
very	NULL
few	NULL
,	NULL
if	NULL
any	NULL
,	NULL
studies	NULL
to	NULL
determine	NULL
the	NULL
precise	NULL
relationship	NULL
between	NULL
RAR	NULL
expression	NULL
and	NULL
response	NULL
to	NULL
retinoids	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
used	NULL
a	NULL
human	NULL
myeloblastic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
as	NULL
a	NULL
model	NULL
for	NULL
investigating	NULL
the	NULL
receptor-specific	NULL
action	NULL
of	NULL
the	NULL
retinoids	NULL
,	NULL
because	NULL
these	NULL
cells	NULL
undergo	NULL
granulocytic	NULL
differentiation	NULL
following	NULL
ATRA	NULL
treatment	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
ATRA	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
potent	NULL
and	NULL
highly	NULL
specific	NULL
inducer	NULL
of	NULL
CD38	NULL
antigen	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
mutant	NULL
subclone	NULL
of	NULL
this	NULL
cell	NULL
line	NULL
(	NULL
HL-6OR	NULL
)	NULL
,	NULL
which	NULL
is	NULL
relatively	NULL
resistant	NULL
to	NULL
ATRA	NULL
(	NULL
25	NULL
)	NULL
,	NULL
failed	NULL
to	NULL
express	NULL
CD38	NULL
when	NULL
treated	NULL
with	NULL
ATRA	NULL
.	NULL

However	NULL
,	NULL
retrovirus-medi-ated	NULL
transduction	NULL
of	NULL
the	NULL
RARa	NULL
gene	NULL
into	NULL
the	NULL
HL-6OR	NULL
subclone	NULL
completely	NULL
restored	NULL
their	NULL
sensitivity	NULL
to	NULL
ATRA	NULL
.	NULL

ATRA	NULL
induced	NULL
a	NULL
similar	NULL
increase	NULL
in	NULL
CD38	NULL
expression	NULL
in	NULL
leukemic	NULL
cells	NULL
from	NULL
APL	NULL
and	NULL
AML	NULL
patients	NULL
.	NULL

Normal	NULL
CD34	NULL
*	NULL
bone	NULL
marrow	NULL
cells	NULL
also	NULL
respond	NULL
to	NULL
ATRA	NULL
in	NULL
terms	NULL
of	NULL
CD38	NULL
expression	NULL
,	NULL
but	NULL
normal	NULL
granulocytes	NULL
failed	NULL
to	NULL
show	NULL
any	NULL
induction	NULL
in	NULL
CD38	NULL
expression	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

HL-60	NULL
,	NULL
an	NULL
AML	NULL
cell	NULL
line	NULL
,	NULL
KG-1	NULL
(	NULL
AML	NULL
)	NULL
,	NULL
and	NULL
K562	NULL
(	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
)	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Tissue	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
retinoic	NULL
acid-resistant	NULL
cell	NULL
line	NULL
HL-60R	NULL
and	NULL
its	NULL
sublines	NULL
transfected	NULL
with	NULL
functional	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RARa	NULL
,	NULL
RAR	NULL
y	NULL
,	NULL
RXRa	NULL
)	NULL
were	NULL
generated	NULL
and	NULL
characterized	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
penicillin	NULL
(	NULL
100	NULL
units/ml	NULL
)	NULL
,	NULL
and	NULL
streptomycin	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
.	NULL

BM	NULL
cells	NULL
from	NULL
3	NULL
patients	NULL
with	NULL
AML	NULL
(	NULL
all	NULL
were	NULL
M2	NULL
by	NULL
the	NULL
French-American-British	NULL
classification	NULL
)	NULL
(	NULL
27	NULL
)	NULL
and	NULL
4	NULL
patients	NULL
with	NULL
APL	NULL
were	NULL
obtained	NULL
at	NULL
diagnosis	NULL
after	NULL
written	NULL
informed	NULL
consent	NULL
following	NULL
standard	NULL
guidelines	NULL
of	NULL
The	NULL
University	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
ATRA	NULL
,	NULL
all-frans-retinoic	NULL
acid	NULL
;	NULL
AML	NULL
,	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
;	NULL
APL	NULL
,	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
;	NULL
BM	NULL
,	NULL
bone	NULL
marrow	NULL
;	NULL
DMSO	NULL
,	NULL
dimethyl	NULL
sulfoxide	NULL
;	NULL
G-CSF	NULL
,	NULL
granulocyte-colony	NULL
stimulating	NULL
factor	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte-mac-rophage-colony	NULL
stimulating	NULL
factor	NULL
;	NULL
IFN-y	NULL
,	NULL
interferon-y	NULL
;	NULL
PE	NULL
,	NULL
phycoerythrin	NULL
;	NULL
S/N	NULL
,	NULL
signal/	NULL
noise	NULL
ratio	NULL
;	NULL
PB	NULL
,	NULL
peripheral	NULL
blood	NULL
;	NULL
RA	NULL
,	NULL
retinoic	NULL
acid	NULL
;	NULL
RAR	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
;	NULL
TPA	NULL
,	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
.	NULL

1746	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

RAR-a-MEDIATED	NULL
CD38	NULL
EXPRESSION	NULL
IN	NULL
MYELOID	NULL
CELLS	NULL
Table	NULL
1	NULL
Expression	NULL
of	NULL
CD38	NULL
antigen	NULL
in	NULL
HL-60	NULL
and	NULL
KG-1	NULL
cells	NULL
following	NULL
their	NULL
differentiation	NULL
into	NULL
mature	NULL
granulocytes	NULL
Results	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
*	NULL
SD	NULL
from	NULL
at	NULL
least	NULL
3	NULL
independent	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

%	NULL
of	NULL
cells	NULL
Metamyelocytes	NULL
+	NULL
CD38	NULL
expression	NULL
Cell	NULL
type	NULL
Treatment	NULL
``	NULL
neutrophils	NULL
CD11b*	NULL
NBT	NULL
*	NULL
(	NULL
SN	NULL
)	NULL
HL-60	NULL
Untreated	NULL
0	NULL
1.5	NULL
+	NULL
0.3	NULL
0.1	NULL
+	NULL
0.1	NULL
9.3	NULL
+	NULL
3.4	NULL
+ATRA	NULL
75.6	NULL
+	NULL
5.1	NULL
67.1	NULL
+	NULL
3.9	NULL
73.4	NULL
+	NULL
6.5	NULL
158.0	NULL
+	NULL
9.4	NULL
+DMSO	NULL
97.6	NULL
+	NULL
6.3	NULL
90.8	NULL
*	NULL
0.3	NULL
ND	NULL
``	NULL
38.4	NULL
+	NULL
0.5	NULL
KG-1	NULL
Untreated	NULL
0	NULL
15.1	NULL
+	NULL
6.6	NULL
0	NULL
13.7	NULL
+	NULL
5.8	NULL
+ATRA	NULL
76.5	NULL
*	NULL
8.5	NULL
85.6	NULL
+	NULL
10.3	NULL
0	NULL
188.2	NULL
+	NULL
12.3	NULL
+DMSO	NULL
ND	NULL
744	NULL
*	NULL
74	NULL
ND	NULL
20.6	NULL
*	NULL
3.2	NULL
*	NULL
Cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
or	NULL
medium	NULL
containing	NULL
2	NULL
um	NULL
ATRA	NULL
or	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
6	NULL
days	NULL
.	NULL

b	NULL
ND	NULL
,	NULL
not	NULL
done	NULL
.	NULL

of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
.	NULL

In	NULL
patients	NULL
with	NULL
APL	NULL
,	NULL
leukemic	NULL
cells	NULL
were	NULL
characterized	NULL
by	NULL
promyelocytic	NULL
morphology	NULL
(	NULL
M3	NULL
by	NULL
French-American-British	NULL
criteria	NULL
)	NULL
and	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
chromosomal	NULL
translocation	NULL
.	NULL

Normal	NULL
BM	NULL
samples	NULL
were	NULL
obtained	NULL
from	NULL
bone	NULL
marrow	NULL
transplant	NULL
donors	NULL
(	NULL
generously	NULL
provided	NULL
by	NULL
Dr.	NULL
R.	NULL
Champlin	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
peripheral	NULL
blood	NULL
samples	NULL
were	NULL
obtained	NULL
from	NULL
healthy	NULL
volunteers	NULL
.	NULL

Mononuclear	NULL
cells	NULL
and	NULL
granulocytes	NULL
were	NULL
separated	NULL
by	NULL
density	NULL
gradient	NULL
centrifugation	NULL
over	NULL
Ficoll-Hypaque	NULL
(	NULL
densities	NULL
1.077	NULL
and	NULL
1.119	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

Cell	NULL
Culture	NULL
.	NULL

In	NULL
experiments	NULL
where	NULL
differentiating	NULL
and	NULL
activating	NULL
agents	NULL
were	NULL
compared	NULL
,	NULL
HL-60	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
ATRA	NULL
(	NULL
100	NULL
nm	NULL
;	NULL
Sigma	NULL
)	NULL
,	NULL
DMSO	NULL
(	NULL
1.3	NULL
%	NULL
v/v	NULL
;	NULL
Sigma	NULL
)	NULL
,	NULL
G-CSF	NULL
(	NULL
50	NULL
ng/ml	NULL
;	NULL
Amgen	NULL
,	NULL
Thousand	NULL
Oaks	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
GM-CSF	NULL
(	NULL
200	NULL
units/ml	NULL
;	NULL
generously	NULL
provided	NULL
by	NULL
Dr.	NULL
S.	NULL
Gillis	NULL
,	NULL
Immunex	NULL
,	NULL
Seattle	NULL
WA	NULL
)	NULL
,	NULL
IFN-y	NULL
(	NULL
500	NULL
units/ml	NULL
;	NULL
Genzyme	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
or	NULL
TPA	NULL
(	NULL
20	NULL
um	NULL
;	NULL
Sigma	NULL
)	NULL
for	NULL
24	NULL
h.	NULL
In	NULL
order	NULL
to	NULL
induce	NULL
the	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
cell	NULL
lines	NULL
and	NULL
cells	NULL
from	NULL
APL	NULL
and	NULL
AML	NULL
patients	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
the	NULL
medium	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
um	NULL
ATRA	NULL
for	NULL
6	NULL
days	NULL
.	NULL

Granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
was	NULL
also	NULL
accomplished	NULL
by	NULL
incubation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
7	NULL
days	NULL
.	NULL

Myeloid	NULL
maturation	NULL
was	NULL
assessed	NULL
by	NULL
morphology	NULL
(	NULL
Wright-Giemsa-stained	NULL
cytospin	NULL
preparations	NULL
)	NULL
,	NULL
immunopheno-typing	NULL
(	NULL
CD11b	NULL
expression	NULL
)	NULL
,	NULL
and	NULL
by	NULL
nitroblue	NULL
tetrazolium	NULL
reduction	NULL
test	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
28	NULL
)	NULL
.	NULL

In	NULL
all	NULL
experiments	NULL
with	NULL
normal	NULL
BM	NULL
and	NULL
PB	NULL
cells	NULL
,	NULL
ATRA	NULL
was	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
100	NULL
nm	NULL
.	NULL

Immunofluorescence	NULL
and	NULL
Flow	NULL
Cytometry	NULL
.	NULL

Expression	NULL
of	NULL
CD38	NULL
protein	NULL
was	NULL
determined	NULL
using	NULL
monoclonal	NULL
antibody	NULL
Leu-17	NULL
(	NULL
PE-conjugated	NULL
;	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

One	NULL
million	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
antibody	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
5	NULL
ug/ml	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
followed	NULL
by	NULL
2	NULL
washes	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

Background	NULL
fluorescence	NULL
was	NULL
determined	NULL
using	NULL
an	NULL
isotypic	NULL
control	NULL
antibody	NULL
(	NULL
PE-labeled	NULL
IgG1	NULL
;	NULL
Becton	NULL
Dickinson	NULL
)	NULL
at	NULL
the	NULL
same	NULL
concentration	NULL
.	NULL

Cells	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
using	NULL
the	NULL
LYSIS	NULL
II	NULL
Research	NULL
Software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

PE	NULL
fluorescence	NULL
was	NULL
detected	NULL
on	NULL
a	NULL
logarithmic	NULL
scale	NULL
.	NULL

The	NULL
percent	NULL
of	NULL
CD38-positive	NULL
cells	NULL
was	NULL
determined	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
cells	NULL
expressing	NULL
CD38	NULL
over	NULL
the	NULL
background	NULL
isotypic	NULL
control	NULL
antibody	NULL
.	NULL

Intensity	NULL
of	NULL
CD38	NULL
expression	NULL
was	NULL
shown	NULL
as	NULL
S/N	NULL
ratios	NULL
defined	NULL
as	NULL
the	NULL
mean	NULL
fluorescence	NULL
of	NULL
CD38-expressing	NULL
cells	NULL
divided	NULL
by	NULL
the	NULL
mean	NULL
fluorescence	NULL
of	NULL
cells	NULL
stained	NULL
with	NULL
the	NULL
isotypic	NULL
control	NULL
antibody	NULL
.	NULL

CD38	NULL
expression	NULL
on	NULL
subsets	NULL
of	NULL
normal	NULL
PB	NULL
and	NULL
BM	NULL
cells	NULL
was	NULL
determined	NULL
in	NULL
2-color	NULL
flow	NULL
cytometric	NULL
experiments	NULL
,	NULL
where	NULL
Leu-17	NULL
PE	NULL
was	NULL
used	NULL
together	NULL
with	NULL
fluorescein	NULL
isothiocyanate-labeled	NULL
lineage	NULL
specific	NULL
antibodies	NULL
(	NULL
Leu-4/CD3	NULL
,	NULL
Leu-14/CD22	NULL
,	NULL
Leu-M1/CD15	NULL
,	NULL
Leu-M3/CD14	NULL
,	NULL
HPCA-2/CD34	NULL
;	NULL
all	NULL
from	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

All	NULL
antibodies	NULL
were	NULL
used	NULL
at	NULL
saturating	NULL
concentrations	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
and	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Appropriate	NULL
isotypic	NULL
controls	NULL
were	NULL
included	NULL
to	NULL
set	NULL
the	NULL
compensation	NULL
on	NULL
the	NULL
FACScan	NULL
.	NULL

CD38	NULL
expression	NULL
on	NULL
antigen-defined	NULL
subpopulations	NULL
was	NULL
measured	NULL
after	NULL
setting	NULL
a	NULL
live-gate	NULL
on	NULL
cells	NULL
positive	NULL
for	NULL
the	NULL
lineage-specific	NULL
antibody	NULL
and	NULL
collecting	NULL
at	NULL
least	NULL
5000	NULL
events	NULL
.	NULL

Statistical	NULL
Analysis	NULL
.	NULL

Mean	NULL
values	NULL
of	NULL
groups	NULL
were	NULL
analyzed	NULL
using	NULL
Student	NULL
's	NULL
t	NULL
test	NULL
for	NULL
paired	NULL
samples	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
CD38	NULL
in	NULL
Differentiated	NULL
HL-60	NULL
and	NULL
KG-1	NULL
Cells	NULL
.	NULL

We	NULL
first	NULL
studied	NULL
the	NULL
expression	NULL
of	NULL
CD38	NULL
in	NULL
HL-60	NULL
cells	NULL
following	NULL
their	NULL
differentiation	NULL
into	NULL
mature	NULL
granulocyte-like	NULL
cells	NULL
by	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
(	NULL
2	NULL
um	NULL
)	NULL
or	NULL
DMSO	NULL
(	NULL
1.3	NULL
%	NULL
,	NULL
v/v	NULL
)	NULL
for	NULL
6	NULL
days	NULL
.	NULL

Most	NULL
cells	NULL
under	NULL
these	NULL
conditions	NULL
exhibited	NULL
the	NULL
characteristics	NULL
of	NULL
differentiated	NULL
myeloid	NULL
cells	NULL
by	NULL
morphology	NULL
,	NULL
immunophenotypically	NULL
,	NULL
and	NULL
their	NULL
ability	NULL
to	NULL
reduce	NULL
nitroblue	NULL
tetrazolium	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

CD38	NULL
expression	NULL
was	NULL
significantly	NULL
increased	NULL
(	NULL
15-18-fold	NULL
)	NULL
in	NULL
ATRA-treated	NULL
HL-60	NULL
cells	NULL
when	NULL
compared	NULL
with	NULL
untreated	NULL
controls	NULL
(	NULL
Table	NULL
1	NULL
;	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
cells	NULL
induced	NULL
to	NULL
differentiate	NULL
by	NULL
treatment	NULL
with	NULL
DMSO	NULL
showed	NULL
only	NULL
a	NULL
moderate	NULL
(	NULL
4-S5-fold	NULL
)	NULL
increase	NULL
in	NULL
CD38	NULL
protein	NULL
,	NULL
even	NULL
though	NULL
a	NULL
majority	NULL
of	NULL
the	NULL
cells	NULL
under	NULL
these	NULL
conditions	NULL
had	NULL
differentiated	NULL
morphologically	NULL
and	NULL
immunophenotypically	NULL
to	NULL
granulocytic	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
CD38	NULL
protein	NULL
was	NULL
also	NULL
studied	NULL
under	NULL
these	NULL
conditions	NULL
in	NULL
KG-1	NULL
cells	NULL
.	NULL

After	NULL
6	NULL
days	NULL
of	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
(	NULL
2	NULL
um	NULL
)	NULL
,	NULL
a	NULL
majority	NULL
of	NULL
the	NULL
cells	NULL
had	NULL
morphologically	NULL
differentiated	NULL
to	NULL
mature	NULL
myeloid	NULL
cells	NULL
(	NULL
metamyelocytes	NULL
and	NULL
neutrophils	NULL
)	NULL
.	NULL

The	NULL
morphological	NULL
differentiation	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
parallel	NULL
increase	NULL
in	NULL
CD33+*/CD11b*	NULL
immunophenotype	NULL
.	NULL

These	NULL
differentiated	NULL
KG-1	NULL
cells	NULL
100	NULL
4	NULL
j	NULL
1	NULL
1	NULL
RPP	NULL
,	NULL
,	NULL
P9	NULL
,	NULL
,	NULL
EP9	NULL
,	NULL
,	NULL
BPY	NULL
;	NULL
,	NULL
(	NULL
199	NULL
!	NULL

Jag	NULL
cL	NULL
g	NULL
alc	NULL
f	NULL
aat	NULL
1	NULL
cala	NULL
1	NULL
i	NULL
i	NULL
;	NULL
1	NULL
RPF	NULL
,	NULL
,	NULL
R9	NULL
;	NULL
,	NULL
GBR	NULL
;	NULL
,	NULL
Bp	NULL
,	NULL
,	NULL
(	NULL
18e	NULL
!	NULL

ag	NULL
Pala	NULL
fr	NULL
ra	NULL
Pa	NULL
ua	NULL
d	NULL
prs	NULL
PR	NULL
T-Prrvim	NULL
104	NULL
ROFOVUARE	NULL
128	NULL
180	NULL
!	NULL

108	NULL
L	NULL
l	NULL
'	NULL
l'Illl	NULL
'	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Representative	NULL
flow	NULL
cytometric	NULL
histograms	NULL
showing	NULL
CD38	NULL
expression	NULL
in	NULL
HL-60	NULL
(	NULL
A	NULL
)	NULL
and	NULL
KG-1	NULL
(	NULL
B	NULL
)	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
Point	NULL
1	NULL
)	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
1.3	NULL
%	NULL
DMSO	NULL
(	NULL
Point	NULL
2	NULL
)	NULL
or	NULL
with	NULL
2	NULL
um	NULL
ATRA	NULL
(	NULL
Point	NULL
3	NULL
)	NULL
for	NULL
6	NULL
days	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
either	NULL
control	NULL
IgG	NULL
,	NULL
(	NULL
Point	NULL
c	NULL
)	NULL
or	NULL
CD38	NULL
antibody	NULL
(	NULL
Leu-17	NULL
)	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

1747	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

RAR-a-MEDIATED	NULL
CD38	NULL
EXPRESSION	NULL
IN	NULL
MYELOID	NULL
CELLS	NULL
i	NULL
5	NULL
200	NULL
§	NULL
3	NULL
HL-60	NULL
HL-6OR	NULL
_	NULL
K562	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

ATRA-induced	NULL
expression	NULL
of	NULL
CD38	NULL
protein	NULL
in	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
lines	NULL
.	NULL

Wild	NULL
type	NULL
(	NULL
HL-60	NULL
)	NULL
,	NULL
RA-resistant	NULL
HL-60	NULL
(	NULL
HL-60R	NULL
)	NULL
,	NULL
and	NULL
K562	NULL
suspension	NULL
cell	NULL
cultures	NULL
were	NULL
incubated	NULL
for	NULL
24	NULL
h	NULL
in	NULL
medium	NULL
alone	NULL
@	NULL
@	NULL
A	NULL
)	NULL
or	NULL
medium	NULL
containing	NULL
1	NULL
pm	NULL
(	NULL
(	NULL
M	NULL
)	NULL
,	NULL
or	NULL
5	NULL
um	NULL
(	NULL
C	NULL
)	NULL
ATRA	NULL
.	NULL

The	NULL
CD38	NULL
protein	NULL
expression	NULL
was	NULL
quantitated	NULL
after	NULL
antibody	NULL
labeling	NULL
by	NULL
flow	NULL
cytometry	NULL
and	NULL
expressed	NULL
as	NULL
S/N	NULL
ratios	NULL
.	NULL

Results	NULL
are	NULL
the	NULL
average	NULL
values	NULL
from	NULL
at	NULL
least	NULL
3	NULL
independent	NULL
experiments	NULL
with	NULL
<	NULL
10	NULL
%	NULL
SD	NULL
.	NULL

accumulated	NULL
very	NULL
high	NULL
levels	NULL
of	NULL
CD38	NULL
(	NULL
11-14-fold	NULL
)	NULL
when	NULL
compared	NULL
with	NULL
untreated	NULL
and	NULL
thus	NULL
undifferentiated	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
;	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

CD38	NULL
Expression	NULL
in	NULL
HL-60R	NULL
Cells	NULL
.	NULL

Next	NULL
we	NULL
determined	NULL
the	NULL
modulation	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
a	NULL
mutant	NULL
subclone	NULL
of	NULL
HL-60	NULL
(	NULL
HL-60R	NULL
)	NULL
that	NULL
exhibited	NULL
relative	NULL
resistance	NULL
to	NULL
ATRA	NULL
.	NULL

Resistance	NULL
of	NULL
HL-60R	NULL
to	NULL
ATRA	NULL
was	NULL
attributed	NULL
to	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
RARa	NULL
gene	NULL
that	NULL
results	NULL
in	NULL
the	NULL
truncation	NULL
of	NULL
52	NULL
amino	NULL
acids	NULL
at	NULL
the	NULL
-COOH	NULL
terminal	NULL
end	NULL
of	NULL
RARa	NULL
protein	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
truncated	NULL
receptor	NULL
has	NULL
markedly	NULL
reduced	NULL
affinity	NULL
for	NULL
its	NULL
ligand	NULL
,	NULL
ATRA	NULL
.	NULL

HL-60R	NULL
cells	NULL
showed	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
resistance	NULL
to	NULL
ATRA	NULL
in	NULL
terms	NULL
of	NULL
their	NULL
inability	NULL
to	NULL
express	NULL
CD38	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
treatment	NULL
of	NULL
HL-6OR	NULL
cells	NULL
with	NULL
as	NULL
high	NULL
as	NULL
5	NULL
um	NULL
ATRA	NULL
induced	NULL
only	NULL
a	NULL
moderate	NULL
degree	NULL
of	NULL
CD38	NULL
expression	NULL
when	NULL
compared	NULL
with	NULL
wild	NULL
type	NULL
HL-60	NULL
cells	NULL
,	NULL
treated	NULL
under	NULL
similar	NULL
conditions	NULL
.	NULL

At	NULL
lower	NULL
doses	NULL
(	NULL
<	NULL
1	NULL
pum	NULL
)	NULL
,	NULL
HL-60R	NULL
cells	NULL
were	NULL
completely	NULL
resistant	NULL
to	NULL
ATRA-induced	NULL
expression	NULL
of	NULL
CD38	NULL
.	NULL

Wild	NULL
type	NULL
HL-60	NULL
cells	NULL
were	NULL
highly	NULL
responsive	NULL
to	NULL
ATRA	NULL
;	NULL
the	NULL
50	NULL
%	NULL
effective	NULL
concentration	NULL
for	NULL
induction	NULL
of	NULL
CD38	NULL
antigen	NULL
was	NULL
approximately	NULL
1	NULL
pm	NULL
(	NULL
23	NULL
)	NULL
and	NULL
showed	NULL
a	NULL
significant	NULL
accumulation	NULL
of	NULL
CD38	NULL
protein	NULL
after	NULL
24-h	NULL
treatment	NULL
with	NULL
0.1	NULL
um	NULL
ATRA	NULL
.	NULL

Interestingly	NULL
,	NULL
even	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
untreated	NULL
HL-60R	NULL
cells	NULL
was	NULL
far	NULL
lower	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
1.5	NULL
+	NULL
0.74	NULL
;	NULL
mean	NULL
+	NULL
SD	NULL
)	NULL
than	NULL
the	NULL
wild	NULL
type	NULL
untreated	NULL
cells	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
9.6	NULL
+	NULL
3.4	NULL
;	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
K562	NULL
cells	NULL
,	NULL
a	NULL
prototype	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
type	NULL
that	NULL
is	NULL
resistant	NULL
to	NULL
ATRA-induced	NULL
differentiation	NULL
,	NULL
failed	NULL
to	NULL
show	NULL
any	NULL
increase	NULL
in	NULL
CD38	NULL
expression	NULL
following	NULL
treatment	NULL
with	NULL
ATRA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Next	NULL
we	NULL
compared	NULL
the	NULL
CD38	NULL
expression	NULL
in	NULL
uninfected	NULL
RA-resistant	NULL
HL-6OR	NULL
cells	NULL
or	NULL
HL-6O0R	NULL
cells	NULL
infected	NULL
with	NULL
LXSN	NULL
retroviral	NULL
vector	NULL
,	NULL
harboring	NULL
a	NULL
complementary	NULL
DNA	NULL
insert	NULL
that	NULL
contained	NULL
a	NULL
complete	NULL
coding	NULL
sequence	NULL
of	NULL
RARa	NULL
,	NULL
RARB	NULL
,	NULL
RARy	NULL
,	NULL
or	NULL
RXRa	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
transfection	NULL
of	NULL
HL-6OR	NULL
cells	NULL
with	NULL
functional	NULL
RARa	NULL
«	NULL
completely	NULL
restored	NULL
the	NULL
sensitivity	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
ATRA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Untreated	NULL
RARa	NULL
transfected	NULL
HL-6OR	NULL
cells	NULL
did	NULL
not	NULL
exhibit	NULL
an	NULL
appreciable	NULL
level	NULL
of	NULL
CD38	NULL
expression	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
1.38	NULL
+	NULL
0.6	NULL
;	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

However	NULL
,	NULL
24-h	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
nm	NULL
ATRA	NULL
induced	NULL
a	NULL
high	NULL
expression	NULL
of	NULL
CD38	NULL
antigen	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
ATRA-induced	NULL
CD38	NULL
expression	NULL
in	NULL
RARa-transfected	NULL
HL-6OR	NULL
cells	NULL
(	NULL
S/N	NULL
ratio	NULL
of	NULL
195.9	NULL
+	NULL
14.1	NULL
)	NULL
was	NULL
even	NULL
higher	NULL
than	NULL
that	NULL
observed	NULL
in	NULL
ATRA-treated	NULL
wild-type	NULL
HL-60	NULL
cells	NULL
(	NULL
S/N	NULL
ratio	NULL
of	NULL
109.0	NULL
+	NULL
24.6	NULL
)	NULL
.	NULL

We	NULL
also	NULL
tested	NULL
HL-60R	NULL
cell	NULL
lines	NULL
that	NULL
were	NULL
transfected	NULL
with	NULL
RARf3	NULL
,	NULL
RAR	NULL
y	NULL
,	NULL
or	NULL
RXRa	NULL
.	NULL

None	NULL
of	NULL
these	NULL
sublines	NULL
showed	NULL
constitutive	NULL
expression	NULL
of	NULL
CD38	NULL
,	NULL
and	NULL
treatment	NULL
with	NULL
100	NULL
nm	NULL
ATRA	NULL
for	NULL
24	NULL
h	NULL
induced	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
CD38	NULL
protein	NULL
in	NULL
RARB	NULL
(	NULL
S/N	NULL
ratio	NULL
of	NULL
9.3	NULL
)	NULL
and	NULL
RARy	NULL
(	NULL
S/N	NULL
ratio	NULL
of	NULL
49.6	NULL
)	NULL
transfected	NULL
HL-6OR	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
no	NULL
significant	NULL
induction	NULL
of	NULL
CD38	NULL
protein	NULL
was	NULL
observed	NULL
in	NULL
HL-6OR	NULL
cells	NULL
transfected	NULL
with	NULL
RXRa	NULL
(	NULL
S/N	NULL
ratio	NULL
1.59	NULL
+	NULL
0.29	NULL
;	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
long	NULL
term	NULL
culture	NULL
(	NULL
6	NULL
days	NULL
)	NULL
of	NULL
transfected	NULL
cell	NULL
lines	NULL
(	NULL
RARa	NULL
,	NULL
RAR	NULL
,	NULL
RARy	NULL
,	NULL
and	NULL
RXRa	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
failed	NULL
to	NULL
alter	NULL
CD38	NULL
expression	NULL
appreciably	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
as	NULL
previously	NULL
observed	NULL
(	NULL
26	NULL
)	NULL
,	NULL
under	NULL
these	NULL
conditions	NULL
(	NULL
100	NULL
nm	NULL
,	NULL
6	NULL
days	NULL
)	NULL
a	NULL
majority	NULL
of	NULL
the	NULL
cells	NULL
from	NULL
all	NULL
4	NULL
transfected	NULL
subclones	NULL
underwent	NULL
the	NULL
morphological	NULL
changes	NULL
characteristic	NULL
of	NULL
granulocytic	NULL
differentiation	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
functional	NULL
receptors	NULL
.	NULL

In	NULL
order	NULL
to	NULL
ascertain	NULL
whether	NULL
ATRA	NULL
is	NULL
a	NULL
specific	NULL
inducer	NULL
of	NULL
CD38	NULL
expression	NULL
,	NULL
we	NULL
tested	NULL
several	NULL
other	NULL
differentiation-inducing	NULL
agents	NULL
and	NULL
compared	NULL
their	NULL
ability	NULL
to	NULL
induce	NULL
CD38	NULL
in	NULL
HL-60R	NULL
cells	NULL
and	NULL
their	NULL
RARa	NULL
or	NULL
RXRa	NULL
transfected	NULL
subclones	NULL
.	NULL

Results	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
revealed	NULL
that	NULL
induction	NULL
of	NULL
CD38	NULL
is	NULL
a	NULL
specific	NULL
response	NULL
of	NULL
these	NULL
cells	NULL
towards	NULL
ATRA	NULL
.	NULL

Other	NULL
differentiation	NULL
agents	NULL
such	NULL
as	NULL
DMSO	NULL
,	NULL
G-CSF	NULL
,	NULL
GM-CSF	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
TPA	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
CD38	NULL
expression	NULL
in	NULL
either	NULL
HL-6OR	NULL
cells	NULL
or	NULL
its	NULL
transfected	NULL
subclones	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
reported	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
retinoids	NULL
to	NULL
induce	NULL
differentiation	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
normal	NULL
and	NULL
malignant	NULL
cell	NULL
types	NULL
can	NULL
be	NULL
greatly	NULL
increased	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
agents	NULL
that	NULL
elevate	NULL
intracellular	NULL
cyclic	NULL
AMP	NULL
(	NULL
15	NULL
,	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
dibutyryl	NULL
HL-6OR-RARoc	NULL
6	NULL
3	NULL
god	NULL
$	NULL
o	NULL
d	NULL
fo	NULL
ll	NULL
®	NULL
(	NULL
d	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

ATRA-induced	NULL
expression	NULL
of	NULL
CD38	NULL
in	NULL
various	NULL
HL-60	NULL
cell	NULL
lines	NULL
.	NULL

Different	NULL
HL-60	NULL
cell	NULL
lines	NULL
(	NULL
wild	NULL
type	NULL
,	NULL
RA-resistant	NULL
,	NULL
RARa	NULL
,	NULL
RARB	NULL
,	NULL
RARy	NULL
,	NULL
and	NULL
RXRa	NULL
retroviral	NULL
vector-transduced	NULL
HL-60R	NULL
cells	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
@	NULL
I	NULL
)	NULL
or	NULL
medium	NULL
containing	NULL
100	NULL
n	NULL
ATRA	NULL
(	NULL
C	NULL
)	NULL
for	NULL
24	NULL
h.	NULL
The	NULL
level	NULL
CD38	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Results	NULL
are	NULL
from	NULL
representative	NULL
experiments	NULL
from	NULL
3	NULL
independent	NULL
observations	NULL
.	NULL

1748	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

RAR-a-MEDIATED	NULL
CD38	NULL
EXPRESSION	NULL
IN	NULL
MYELOID	NULL
CELLS	NULL
5	NULL
0	NULL
7	NULL
]	NULL
4	NULL
0	NULL
7	NULL
c	NULL
Fe	NULL
b	NULL
L	NULL
©	NULL
al-	NULL
,	NULL
Pa	NULL
3	NULL
0	NULL
{	NULL
a	NULL
B	NULL
8	NULL
to	NULL
B	NULL
pr	NULL
20	NULL
ait	NULL
d	NULL
|	NULL
C	NULL
E	NULL
1	NULL
0	NULL
m~	NULL
b	NULL
a	NULL
}	NULL
T	NULL
o	NULL
\	NULL
b	NULL
a	NULL
}	NULL
T	NULL
2	NULL
3	NULL
3	NULL
1g	NULL
106	NULL
106	NULL
10	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

CD38	NULL
expression	NULL
in	NULL
HL-60R	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
,	NULL
RAR-a	NULL
:	NULL
transfected	NULL
HL-6OR	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
RXRa	NULL
:	NULL
transfected	NULL
HL-6OR	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

IgG1	NULL
isotypic	NULL
control	NULL
(	NULL
Line	NULL
a	NULL
)	NULL
and	NULL
CD38	NULL
(	NULL
Line	NULL
b	NULL
)	NULL
in	NULL
untreated	NULL
cells	NULL
,	NULL
IgG1	NULL
isotypic	NULL
control	NULL
(	NULL
Line	NULL
c	NULL
)	NULL
and	NULL
CD38	NULL
(	NULL
Line	NULL
d	NULL
)	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
100	NULL
nm	NULL
ATRA	NULL
for	NULL
24	NULL
h	NULL
is	NULL
shown	NULL
.	NULL

cyclic	NULL
AMP	NULL
to	NULL
affect	NULL
ATRA-induced	NULL
expression	NULL
of	NULL
CD38	NULL
in	NULL
HL-60	NULL
cells	NULL
.	NULL

Results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
demonstrated	NULL
that	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
dibutyryl	NULL
cyclic	NULL
AMP	NULL
alone	NULL
induced	NULL
a	NULL
small	NULL
increase	NULL
(	NULL
2-fold	NULL
)	NULL
in	NULL
the	NULL
level	NULL
of	NULL
CD38	NULL
.	NULL

There	NULL
was	NULL
a	NULL
much	NULL
larger	NULL
increase	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
CD38	NULL
protein	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
ATRA	NULL
alone	NULL
(	NULL
19-fold	NULL
)	NULL
.	NULL

Control	NULL
ATRA	NULL
DBC	NULL
-	NULL
ATRA+DBC	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Effect	NULL
of	NULL
dibutyryl	NULL
cyclic	NULL
AMP	NULL
on	NULL
ATRA-induced	NULL
expression	NULL
of	NULL
CD38	NULL
.	NULL

The	NULL
level	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
untreated	NULL
HL-60	NULL
cells	NULL
(	NULL
Control	NULL
)	NULL
and	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
either	NULL
1	NULL
mm	NULL
dibutyryl	NULL
cyclic	NULL
AMP	NULL
(	NULL
dibutyry	NULL
]	NULL
cyclic	NULL
adenosine	NULL
monophosphate	NULL
;	NULL
DBC	NULL
)	NULL
,	NULL
1	NULL
nm	NULL
ATRA	NULL
,	NULL
or	NULL
ATRA	NULL
plus	NULL
DBC	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
values	NULL
shown	NULL
represent	NULL
the	NULL
mean	NULL
and	NULL
ranges	NULL
of	NULL
duplicate	NULL
determinations	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
dibutyryl	NULL
cyclic	NULL
AMP	NULL
and	NULL
ATRA	NULL
was	NULL
slightly	NULL
more	NULL
effective	NULL
(	NULL
26-fold	NULL
)	NULL
than	NULL
either	NULL
agent	NULL
alone	NULL
in	NULL
inducing	NULL
the	NULL
CD38	NULL
antigen	NULL
expression	NULL
.	NULL

Induction	NULL
of	NULL
CD38	NULL
by	NULL
ATRA	NULL
in	NULL
APL	NULL
and	NULL
AML	NULL
Cells	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
whether	NULL
CD38	NULL
induction	NULL
was	NULL
associated	NULL
with	NULL
differentiation	NULL
of	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
,	NULL
we	NULL
studied	NULL
CD38	NULL
expression	NULL
in	NULL
cells	NULL
from	NULL
APL	NULL
and	NULL
AML	NULL
patients	NULL
,	NULL
following	NULL
their	NULL
in	NULL
vitro	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
ATRA	NULL
.	NULL

Six-day	NULL
culture	NULL
of	NULL
cells	NULL
from	NULL
4	NULL
APL	NULL
patients	NULL
with	NULL
2	NULL
um	NULL
ATRA	NULL
led	NULL
to	NULL
prominent	NULL
morphological	NULL
changes	NULL
in	NULL
these	NULL
cells	NULL
that	NULL
were	NULL
characteristic	NULL
of	NULL
mature	NULL
granulocytes	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

The	NULL
CD38	NULL
expression	NULL
in	NULL
ATRA-treated	NULL
APL	NULL
cells	NULL
was	NULL
significantly	NULL
higher	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
20.8	NULL
+	NULL
14.2	NULL
)	NULL
when	NULL
compared	NULL
with	NULL
untreated	NULL
controls	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
2.55	NULL
+	NULL
1.46	NULL
)	NULL
or	NULL
with	NULL
normal	NULL
peripheral	NULL
blood	NULL
neutrophils	NULL
(	NULL
S/N	NULL
ratio	NULL
1.9	NULL
+	NULL
0.65	NULL
,	NULL
determined	NULL
in	NULL
neutrophils	NULL
isolated	NULL
from	NULL
5	NULL
normal	NULL
individuals	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
induction	NULL
in	NULL
CD38	NULL
expression	NULL
Table	NULL
2	NULL
Induction	NULL
of	NULL
CD38	NULL
in	NULL
HL-60	NULL
cells	NULL
after	NULL
treatment	NULL
(	NULL
24	NULL
h	NULL
)	NULL
with	NULL
various	NULL
differentiating	NULL
agents	NULL
Results	NULL
are	NULL
the	NULL
mean	NULL
values	NULL
from	NULL
2	NULL
to	NULL
4	NULL
experiments	NULL
in	NULL
duplicates	NULL
with	NULL
less	NULL
than	NULL
10	NULL
%	NULL
deviation	NULL
from	NULL
the	NULL
mean	NULL
.	NULL

CD38	NULL
expression	NULL
(	NULL
S/N	NULL
ratio	NULL
)	NULL
ATRA	NULL
DMSO	NULL
G-CSF	NULL
GM-CSF	NULL
IFN-y	NULL
TPA	NULL
Cells	NULL
Control	NULL
(	NULL
100	NULL
nm	NULL
)	NULL
(	NULL
1.3	NULL
%	NULL
,	NULL
viv	NULL
)	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
(	NULL
200	NULL
units/ml	NULL
)	NULL
(	NULL
200	NULL
units/ml	NULL
)	NULL
(	NULL
20	NULL
pm	NULL
)	NULL
HL-60	NULL
8.1	NULL
72.3	NULL
7.0	NULL
64	NULL
6.175	NULL
5.22	NULL
5.6	NULL
HL-60R	NULL
0.97	NULL
1.9	NULL
1.10	NULL
1.27	NULL
111	NULL
0.99	NULL
0.99	NULL
HL-60R	NULL
RAR-a	NULL
``	NULL
0.98	NULL
195.9	NULL
0.99	NULL
1.12	NULL
1.05	NULL
1.05	NULL
1.00	NULL
HL-60R	NULL
RXR-a	NULL
``	NULL
0.97	NULL
1.6	NULL
1.05	NULL
1.15	NULL
1.18	NULL
1.05	NULL
1.00	NULL
``	NULL
HL-60R	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
functional	NULL
RAR-a	NULL
receptor	NULL
.	NULL

®	NULL
HL-60R	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
functional	NULL
RXR-	NULL
«	NULL
receptor	NULL
.	NULL

1749	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

RAR-a-MEDIATED	NULL
CD38	NULL
EXPRESSION	NULL
IN	NULL
MYELOID	NULL
CELLS	NULL
Table	NULL
3	NULL
Expression	NULL
of	NULL
CD38	NULL
in	NULL
APL	NULL
cells	NULL
after	NULL
ATRA-induced	NULL
cytodifferentiation	NULL
``	NULL
Results	NULL
are	NULL
the	NULL
mean	NULL
values	NULL
of	NULL
duplicate	NULL
experiments	NULL
.	NULL

%	NULL
metamyelocytes	NULL
+	NULL
CD38	NULL
expression	NULL
Patient	NULL
no	NULL
.	NULL

Treatment	NULL
``	NULL
neutrophils	NULL
%	NULL
positive	NULL
cells	NULL
S/N	NULL
1	NULL
No	NULL
treatment	NULL
14.5	NULL
24.3	NULL
2.45	NULL
+ATRA	NULL
96.0	NULL
65.8	NULL
8.47	NULL
2	NULL
No	NULL
treatment	NULL
1.8	NULL
35.6	NULL
2.21	NULL
+ATRA	NULL
82.2	NULL
98.8	NULL
21.28	NULL
3	NULL
No	NULL
treatment	NULL
16.0	NULL
85.4	NULL
4.54	NULL
+ATRA	NULL
56.5	NULL
98.8	NULL
40.60	NULL
4	NULL
No	NULL
treatment	NULL
4.8	NULL
0	NULL
1.01	NULL
+ATRA	NULL
62.0	NULL
95.3	NULL
12.85	NULL
``	NULL
Cells	NULL
were	NULL
cultured	NULL
in	NULL
vitro	NULL
for	NULL
6	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
2	NULL
um	NULL
ATRA	NULL
.	NULL

(	NULL
2.5-5-fold	NULL
)	NULL
was	NULL
observed	NULL
in	NULL
cells	NULL
from	NULL
AML	NULL
patients	NULL
after	NULL
their	NULL
in	NULL
vitro	NULL
treatment	NULL
with	NULL
ATRA	NULL
(	NULL
2	NULL
um	NULL
,	NULL
6	NULL
days	NULL
)	NULL
.	NULL

However	NULL
,	NULL
unlike	NULL
in	NULL
APL	NULL
cells	NULL
,	NULL
induction	NULL
of	NULL
CD38	NULL
antigen	NULL
in	NULL
AML	NULL
cells	NULL
by	NULL
ATRA	NULL
was	NULL
not	NULL
accompanied	NULL
by	NULL
any	NULL
morphological	NULL
or	NULL
immunophenotypic	NULL
changes	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
ATRA	NULL
on	NULL
CD38	NULL
Expression	NULL
on	NULL
Normal	NULL
Hematopoietic	NULL
Cells	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
ATRA	NULL
can	NULL
modulate	NULL
CD38	NULL
expression	NULL
in	NULL
normal	NULL
hematopoietic	NULL
cells	NULL
,	NULL
we	NULL
studied	NULL
CD38	NULL
expression	NULL
in	NULL
normal	NULL
BM	NULL
and	NULL
PB	NULL
cells	NULL
after	NULL
24	NULL
h	NULL
of	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
100	NULL
nm	NULL
ATRA	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

After	NULL
ATRA	NULL
treatment	NULL
,	NULL
analysis	NULL
of	NULL
the	NULL
entire	NULL
BM	NULL
mononuclear	NULL
cell	NULL
population	NULL
revealed	NULL
neither	NULL
an	NULL
increase	NULL
in	NULL
CD38-positive	NULL
cells	NULL
nor	NULL
an	NULL
increase	NULL
in	NULL
CD38	NULL
protein	NULL
levels	NULL
.	NULL

However	NULL
,	NULL
CD38	NULL
expression	NULL
in	NULL
normal	NULL
CD34+*	NULL
positive	NULL
BM	NULL
cells	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
2-color	NULL
flow	NULL
cytometry	NULL
,	NULL
was	NULL
significantly	NULL
higher	NULL
after	NULL
culture	NULL
with	NULL
ATRA	NULL
compared	NULL
to	NULL
untreated	NULL
controls	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
;	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

In	NULL
normal	NULL
PB	NULL
mononuclear	NULL
cells	NULL
,	NULL
there	NULL
was	NULL
a	NULL
slight	NULL
increase	NULL
in	NULL
the	NULL
percentage	NULL
of	NULL
CD38-positive	NULL
cells	NULL
,	NULL
following	NULL
their	NULL
culture	NULL
with	NULL
ATRA	NULL
.	NULL

Analysis	NULL
of	NULL
PB	NULL
cell	NULL
subpopulations	NULL
indicated	NULL
that	NULL
this	NULL
increase	NULL
was	NULL
due	NULL
to	NULL
a	NULL
significantly	NULL
increased	NULL
proportion	NULL
of	NULL
CD38	NULL
expressing	NULL
T-lymphocytes	NULL
(	NULL
CD3	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
percentages	NULL
of	NULL
CD38-positive	NULL
B-lymphocytes	NULL
(	NULL
CD22	NULL
)	NULL
and	NULL
monocytes	NULL
(	NULL
CD14	NULL
)	NULL
were	NULL
un-changed	NULL
.	NULL

Intensity	NULL
of	NULL
CD38	NULL
expression	NULL
was	NULL
not	NULL
influenced	NULL
by	NULL
ATRA	NULL
in	NULL
normal	NULL
T-lymphocytes	NULL
and	NULL
monocytes	NULL
,	NULL
but	NULL
an	NULL
increase	NULL
in	NULL
S/N	NULL
ratios	NULL
was	NULL
observed	NULL
in	NULL
B-lymphocytes	NULL
.	NULL

CD38	NULL
was	NULL
not	NULL
expressed	NULL
on	NULL
normal	NULL
granulocytes	NULL
(	NULL
CD15	NULL
)	NULL
,	NULL
nor	NULL
could	NULL
it	NULL
be	NULL
induced	NULL
by	NULL
treatment	NULL
with	NULL
ATRA	NULL
.	NULL

There	NULL
was	NULL
no	NULL
appreciable	NULL
change	NULL
observed	NULL
in	NULL
S/N	NULL
ratios	NULL
of	NULL
CD34	NULL
,	NULL
CD3	NULL
,	NULL
CD22	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
CD15	NULL
in	NULL
BM	NULL
or	NULL
PB	NULL
cells	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
ATRA	NULL
or	NULL
left	NULL
untreated	NULL
in	NULL
cultures	NULL
for	NULL
24	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
been	NULL
interested	NULL
in	NULL
understanding	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
retinoids	NULL
regulate	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
normal	NULL
and	NULL
transformed	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Retinoids	NULL
,	NULL
and	NULL
RA	NULL
in	NULL
particular	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
influence	NULL
the	NULL
proliferation	NULL
and	NULL
differentiation	NULL
functions	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

These	NULL
biological	NULL
effects	NULL
of	NULL
RA	NULL
are	NULL
believed	NULL
to	NULL
be	NULL
due	NULL
to	NULL
their	NULL
ability	NULL
to	NULL
interact	NULL
with	NULL
specific	NULL
nuclear	NULL
receptors	NULL
that	NULL
in	NULL
turn	NULL
result	NULL
in	NULL
altered	NULL
expression	NULL
of	NULL
certain	NULL
genes	NULL
in	NULL
target	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
there	NULL
are	NULL
not	NULL
many	NULL
proteins	NULL
whose	NULL
expression	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
under	NULL
the	NULL
direct	NULL
control	NULL
of	NULL
RA	NULL
.	NULL

The	NULL
CD38	NULL
antigen	NULL
is	NULL
a	NULL
multilineage	NULL
molecule	NULL
(	NULL
2-8	NULL
)	NULL
whose	NULL
expression	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
an	NULL
activated	NULL
state	NULL
of	NULL
lymphocytes	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

In	NULL
cells	NULL
belonging	NULL
to	NULL
the	NULL
myeloid	NULL
lineage	NULL
,	NULL
CD38	NULL
is	NULL
present	NULL
mainly	NULL
on	NULL
precursor	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

There	NULL
is	NULL
no	NULL
information	NULL
available	NULL
on	NULL
the	NULL
endogenous	NULL
factors	NULL
that	NULL
modulate	NULL
the	NULL
expression	NULL
of	NULL
CD38	NULL
in	NULL
myeloid	NULL
or	NULL
even	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Recently	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
ATRA	NULL
is	NULL
a	NULL
highly	NULL
potent	NULL
inducer	NULL
of	NULL
CD38	NULL
expression	NULL
,	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
,	NULL
in	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
(	NULL
23	NULL
)	NULL
.	NULL

As	NULL
low	NULL
a	NULL
dose	NULL
of	NULL
ATRA	NULL
as	NULL
100	NULL
fm	NULL
is	NULL
able	NULL
to	NULL
induce	NULL
large	NULL
increases	NULL
in	NULL
CD38	NULL
expression	NULL
,	NULL
and	NULL
this	NULL
increase	NULL
is	NULL
due	NULL
to	NULL
rapid	NULL
accumulation	NULL
of	NULL
CD38	NULL
mRNA	NULL
after	NULL
addition	NULL
of	NULL
ATRA	NULL
to	NULL
the	NULL
cultured	NULL
cells	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
a	NULL
similar	NULL
increase	NULL
in	NULL
CD38	NULL
expression	NULL
by	NULL
ATRA	NULL
has	NULL
been	NULL
reported	NULL
by	NULL
Kontani	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
suggested	NULL
to	NULL
us	NULL
that	NULL
induction	NULL
of	NULL
this	NULL
antigen	NULL
could	NULL
be	NULL
a	NULL
useful	NULL
tool	NULL
to	NULL
study	NULL
retinoid-mediated	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
normal	NULL
and	NULL
transformed	NULL
myeloid	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
ATRA	NULL
is	NULL
a	NULL
general	NULL
inducer	NULL
of	NULL
CD38	NULL
antigen	NULL
in	NULL
normal	NULL
and	NULL
transformed	NULL
myeloid	NULL
cells	NULL
and	NULL
that	NULL
RARa	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
mediating	NULL
this	NULL
effect	NULL
in	NULL
HL-60	NULL
myeloid	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
CD38	NULL
is	NULL
not	NULL
a	NULL
part	NULL
of	NULL
the	NULL
regular	NULL
differentiation	NULL
pathway	NULL
of	NULL
myeloid	NULL
cells	NULL
.	NULL

In	NULL
normal	NULL
myelopoiesis	NULL
,	NULL
CD38	NULL
is	NULL
expressed	NULL
by	NULL
cells	NULL
during	NULL
early	NULL
stages	NULL
of	NULL
myeloid	NULL
differentiation	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
then	NULL
it	NULL
declines	NULL
during	NULL
myeloid	NULL
maturation	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
confirm	NULL
the	NULL
observation	NULL
that	NULL
normal	NULL
mature	NULL
granulocytes	NULL
do	NULL
not	NULL
express	NULL
CD38	NULL
.	NULL

Moreover	NULL
,	NULL
treatment	NULL
of	NULL
normal	NULL
granulocytes	NULL
with	NULL
ATRA	NULL
failed	NULL
to	NULL
augment	NULL
CD38	NULL
expression	NULL
that	NULL
was	NULL
in	NULL
contrast	NULL
to	NULL
high	NULL
CD38	NULL
expression	NULL
observed	NULL
in	NULL
APL	NULL
cells	NULL
that	NULL
were	NULL
morphologically	NULL
differentiated	NULL
to	NULL
mature	NULL
granulocytes	NULL
,	NULL
following	NULL
their	NULL
in	NULL
vitro	NULL
treatment	NULL
with	NULL
ATRA	NULL
.	NULL

Although	NULL
RARs	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
the	NULL
ultimate	NULL
mediators	NULL
of	NULL
retinoid	NULL
action	NULL
for	NULL
gene	NULL
regulation	NULL
,	NULL
very	NULL
little	NULL
data	NULL
are	NULL
available	NULL
to	NULL
support	NULL
this	NULL
contention	NULL
;	NULL
however	NULL
,	NULL
that	NULL
biological	NULL
activity	NULL
of	NULL
several	NULL
retinoids	NULL
correlates	NULL
well	NULL
with	NULL
their	NULL
affinity	NULL
for	NULL
RARs	NULL
(	NULL
31	NULL
)	NULL
is	NULL
one	NULL
piece	NULL
of	NULL
supportive	NULL
evidence	NULL
.	NULL

More	NULL
direct	NULL
evidence	NULL
came	NULL
from	NULL
our	NULL
earlier	NULL
studies	NULL
with	NULL
HL-60	NULL
cells	NULL
,	NULL
where	NULL
transduction	NULL
of	NULL
RARa	NULL
via	NULL
retroviral	NULL
vector	NULL
in	NULL
RA-resistant	NULL
cells	NULL
was	NULL
shown	NULL
to	NULL
restore	NULL
the	NULL
responsiveness	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
ATRA	NULL
(	NULL
26	NULL
,	NULL
32	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
used	NULL
a	NULL
similar	NULL
approach	NULL
to	NULL
determine	NULL
participation	NULL
of	NULL
RARs	NULL
in	NULL
ATRA-induced	NULL
up-regulation	NULL
of	NULL
CD38	NULL
expression	NULL
.	NULL

Specific	NULL
nuclear	NULL
RARs	NULL
in	NULL
a	NULL
RA-resistant	NULL
subclone	NULL
of	NULL
HL-60	NULL
cells	NULL
(	NULL
HL-6OR	NULL
)	NULL
exhibit	NULL
a	NULL
decreased	NULL
affinity	NULL
for	NULL
ATRA	NULL
due	NULL
to	NULL
truncation	NULL
of	NULL
52	NULL
amino	NULL
acids	NULL
at	NULL
the	NULL
COOH	NULL
terminal	NULL
end	NULL
of	NULL
RARa	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
treatment	NULL
of	NULL
HL-6O0R	NULL
cells	NULL
with	NULL
Table	NULL
4	NULL
Expression	NULL
of	NULL
CD38	NULL
in	NULL
AML	NULL
cells	NULL
treated	NULL
with	NULL
ATRA	NULL
Results	NULL
are	NULL
the	NULL
average	NULL
values	NULL
from	NULL
duplicate	NULL
experiments	NULL
.	NULL

%	NULL
of	NULL
cells	NULL
CD38	NULL
expression	NULL
Patient	NULL
Metamyelocytes	NULL
+	NULL
%	NULL
positive	NULL
ratio	NULL
Treatment	NULL
``	NULL
seg	NULL
CD11b*	NULL
CD15*	NULL
cells	NULL
S/N	NULL
1	NULL
No	NULL
treatment	NULL
0	NULL
3.8	NULL
4.7	NULL
89.5	NULL
14.6	NULL
+ATRA	NULL
0	NULL
9.7	NULL
15.1	NULL
94.7	NULL
78.0	NULL
2	NULL
No	NULL
treatment	NULL
23.8	NULL
59.9	NULL
84.5	NULL
77.3	NULL
30.3	NULL
+ATRA	NULL
26.0	NULL
59.3	NULL
85.7	NULL
87.6	NULL
80.0	NULL
3	NULL
No	NULL
treatment	NULL
ND®	NULL
2.8	NULL
24	NULL
99.6	NULL
57.5	NULL
+ATRA	NULL
ND	NULL
6.2	NULL
5.4	NULL
99.8	NULL
161.5	NULL
``	NULL
Cells	NULL
were	NULL
cultured	NULL
in	NULL
vitro	NULL
for	NULL
6	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
2	NULL
um	NULL
ATRA	NULL
.	NULL

*	NULL
Percent	NULL
cells	NULL
with	NULL
metamyelocyte	NULL
and	NULL
neutrophil	NULL
morphology	NULL
.	NULL

©	NULL
ND	NULL
,	NULL
Not	NULL
done	NULL
.	NULL

1750	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

RAR-a-MEDIATED	NULL
CD38	NULL
EXPRESSION	NULL
IN	NULL
MYELOID	NULL
CELLS	NULL
40	NULL
%	NULL
CD38	NULL
positive	NULL
Till	NULL
CD22	NULL
CD14	NULL
CD15	NULL
BM	NULL
_	NULL
CD34	NULL
PB	NULL
CD3	NULL
200	NULL
-	NULL
]	NULL
ud	NULL
t	NULL
a	NULL
tas	NULL
$	NULL
3	NULL
8	NULL
CD38	NULL
EXPRESSION	NULL
(	NULL
S/N	NULL
RATIO	NULL
)	NULL
a	NULL
o	NULL
o	NULL
CMK	NULL
|	NULL
is	NULL
Bm	NULL
-	NULL
CD34	NULL
PB	NULL
_	NULL
CD3	NULL
CD22	NULL
CD14	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Effects	NULL
of	NULL
ATRA	NULL
on	NULL
CD38	NULL
expression	NULL
in	NULL
normal	NULL
bone	NULL
marrow	NULL
and	NULL
peripheral	NULL
blood	NULL
cells	NULL
.	NULL

The	NULL
percentages	NULL
of	NULL
CD38	NULL
positive	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
and	NULL
the	NULL
level	NULL
of	NULL
CD38	NULL
expression	NULL
(	NULL
B	NULL
,	NULL
shown	NULL
as	NULL
S/N	NULL
ratios	NULL
)	NULL
were	NULL
determined	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
and	NULL
cells	NULL
treated	NULL
with	NULL
100	NULL
nm	NULL
ATRA	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
for	NULL
24	NULL
h.	NULL
PB	NULL
,	NULL
PB	NULL
mononuclear	NULL
cells	NULL
;	NULL
BM	NULL
,	NULL
BM	NULL
mononuclear	NULL
cells	NULL
.	NULL

Two-color	NULL
flow	NULL
cytometry	NULL
was	NULL
used	NULL
to	NULL
study	NULL
CD38	NULL
expression	NULL
on	NULL
antigen-defined	NULL
subpopulations	NULL
.	NULL

Following	NULL
treatment	NULL
with	NULL
ATRA	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
CD38-expressing	NULL
T-cells	NULL
(	NULL
CD3	NULL
)	NULL
had	NULL
increased	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

A	NULL
significant	NULL
increase	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
in	NULL
CD38	NULL
protein	NULL
level	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
ATRA-treated	NULL
normal	NULL
CD34	NULL
*	NULL
bone	NULL
marrow	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
CD22*	NULL
peripheral	NULL
blood	NULL
B-lymphocytes	NULL
.	NULL

No	NULL
expression	NULL
of	NULL
CD38	NULL
in	NULL
untreated	NULL
cells	NULL
or	NULL
induction	NULL
following	NULL
their	NULL
treatment	NULL
with	NULL
ATRA	NULL
was	NULL
observed	NULL
in	NULL
normal	NULL
granulocytes	NULL
(	NULL
CD15	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
from	NULL
3	NULL
normal	NULL
bone	NULL
marrow	NULL
samples	NULL
and	NULL
4	NULL
normal	NULL
peripheral	NULL
blood	NULL
samples	NULL
(	NULL
mean	NULL
*	NULL
SD	NULL
)	NULL
.	NULL

CD15	NULL
ATRA	NULL
under	NULL
optimal	NULL
conditions	NULL
(	NULL
1	NULL
um	NULL
,	NULL
24	NULL
h	NULL
)	NULL
,	NULL
failed	NULL
to	NULL
show	NULL
any	NULL
appreciable	NULL
increase	NULL
in	NULL
CD38	NULL
expression	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Retroviral	NULL
vector-mediated	NULL
transduction	NULL
of	NULL
the	NULL
single	NULL
copy	NULL
of	NULL
the	NULL
RARa	NULL
into	NULL
this	NULL
RA-resistant	NULL
HL-60	NULL
subclone	NULL
completely	NULL
restored	NULL
the	NULL
ability	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
induce	NULL
CD38	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CD38	NULL
was	NULL
very	NULL
weakly	NULL
induced	NULL
in	NULL
the	NULL
HL-6OR	NULL
cells	NULL
that	NULL
were	NULL
transfected	NULL
with	NULL
RARBG	NULL
or	NULL
RARy	NULL
,	NULL
and	NULL
no	NULL
up-regulation	NULL
of	NULL
CD38	NULL
was	NULL
seen	NULL
in	NULL
the	NULL
RXRa	NULL
transfected	NULL
cells	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
transduced	NULL
cell	NULL
lines	NULL
express	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
their	NULL
transduced	NULL
receptors	NULL
(	NULL
300	NULL
to	NULL
2000	NULL
receptors/cell	NULL
)	NULL
compared	NULL
to	NULL
the	NULL
untreated	NULL
HL-6OR	NULL
cells	NULL
(	NULL
125	NULL
receptors/cell	NULL
)	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
K562	NULL
,	NULL
a	NULL
human	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
cell	NULL
line	NULL
,	NULL
was	NULL
completely	NULL
unresponsive	NULL
to	NULL
ATRA-induced	NULL
effects	NULL
on	NULL
CD38	NULL
.	NULL

This	NULL
unresponsiveness	NULL
of	NULL
K562	NULL
cells	NULL
might	NULL
be	NULL
attributed	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
very	NULL
low	NULL
level	NULL
(	NULL
80	NULL
receptors/cell	NULL
)	NULL
of	NULL
RARa	NULL
compared	NULL
with	NULL
550	NULL
receptors/cell	NULL
in	NULL
HL-60	NULL
cells	NULL
,	NULL
which	NULL
respond	NULL
to	NULL
ATRA	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
RARs	NULL
may	NULL
or	NULL
may	NULL
not	NULL
be	NULL
sufficient	NULL
to	NULL
render	NULL
a	NULL
cell	NULL
responsive	NULL
to	NULL
the	NULL
growth	NULL
inhibitory	NULL
or	NULL
differentiation-inducing	NULL
effects	NULL
of	NULL
retinoids	NULL
.	NULL

However	NULL
,	NULL
we	NULL
feel	NULL
that	NULL
presence	NULL
of	NULL
functional	NULL
RARa	NULL
in	NULL
myeloid	NULL
cells	NULL
is	NULL
sufficient	NULL
to	NULL
make	NULL
these	NULL
cells	NULL
responsive	NULL
to	NULL
ATRA	NULL
in	NULL
terms	NULL
of	NULL
inducing	NULL
CD38	NULL
expression	NULL
.	NULL

For	NULL
example	NULL
,	NULL
AML	NULL
cells	NULL
are	NULL
known	NULL
to	NULL
express	NULL
RARa	NULL
(	NULL
34	NULL
)	NULL
,	NULL
though	NULL
they	NULL
failed	NULL
to	NULL
differentiate	NULL
morphologically	NULL
and	NULL
immunophenotypically	NULL
,	NULL
yet	NULL
showed	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
CD38	NULL
antigen	NULL
following	NULL
ATRA	NULL
treatment	NULL
.	NULL

Conversely	NULL
,	NULL
HL-6OR	NULL
cells	NULL
responded	NULL
to	NULL
ATRA	NULL
treatment	NULL
in	NULL
terms	NULL
of	NULL
CD38	NULL
expression	NULL
,	NULL
only	NULL
when	NULL
they	NULL
were	NULL
transduced	NULL
to	NULL
express	NULL
RARa	NULL
;	NULL
whereas	NULL
transduction	NULL
of	NULL
RARB	NULL
,	NULL
RARy	NULL
,	NULL
or	NULL
RXRa	NULL
receptors	NULL
could	NULL
not	NULL
reconstitute	NULL
CD38	NULL
induction	NULL
ability	NULL
in	NULL
HL-6OR	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
.	NULL

Interestingly	NULL
,	NULL
all	NULL
4	NULL
subclones	NULL
(	NULL
RARa	NULL
,	NULL
RARB	NULL
,	NULL
RARy	NULL
,	NULL
and	NULL
RXRa	NULL
)	NULL
did	NULL
differentiate	NULL
to	NULL
mature	NULL
granulocytic	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
(	NULL
100	NULL
nm	NULL
,	NULL
6	NULL
days	NULL
)	NULL
treatment	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
induction	NULL
of	NULL
CD38	NULL
by	NULL
ATRA	NULL
is	NULL
mediated	NULL
in	NULL
a	NULL
receptor-specific	NULL
manner	NULL
and	NULL
is	NULL
exclusively	NULL
associated	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
functional	NULL
RARa	NULL
.	NULL

From	NULL
these	NULL
studies	NULL
,	NULL
it	NULL
is	NULL
also	NULL
evident	NULL
that	NULL
induction	NULL
of	NULL
CD38	NULL
by	NULL
ATRA	NULL
is	NULL
a	NULL
differentiation-independent	NULL
phenomenon	NULL
.	NULL

One	NULL
striking	NULL
feature	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
ATRA	NULL
on	NULL
CD38	NULL
induction	NULL
in	NULL
HL-60	NULL
cells	NULL
was	NULL
its	NULL
remarkable	NULL
specificity	NULL
.	NULL

We	NULL
took	NULL
advantage	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
HL-60	NULL
cells	NULL
could	NULL
be	NULL
induced	NULL
to	NULL
differentiate	NULL
in	NULL
response	NULL
to	NULL
a	NULL
diverse	NULL
group	NULL
of	NULL
chemical	NULL
agents	NULL
and	NULL
biological	NULL
response	NULL
modifiers	NULL
(	NULL
15	NULL
,	NULL
35	NULL
)	NULL
.	NULL

The	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
these	NULL
agents	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
different	NULL
from	NULL
the	NULL
effects	NULL
of	NULL
ATRA	NULL
.	NULL

Compounds	NULL
such	NULL
as	NULL
DMSO	NULL
,	NULL
for	NULL
example	NULL
,	NULL
differentiate	NULL
HL-60	NULL
into	NULL
cells	NULL
that	NULL
are	NULL
functionally	NULL
,	NULL
morpho-logically	NULL
,	NULL
and	NULL
immunophenotypically	NULL
similar	NULL
to	NULL
ATRA-treated	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
only	NULL
ATRA-treated	NULL
cells	NULL
showed	NULL
an	NULL
induction	NULL
in	NULL
CD38	NULL
expression	NULL
.	NULL

Treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
other	NULL
differentiating	NULL
agents	NULL
such	NULL
as	NULL
,	NULL
TPA	NULL
,	NULL
IFN-y	NULL
,	NULL
G-CSF	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
even	NULL
DMSO	NULL
,	NULL
did	NULL
not	NULL
result	NULL
in	NULL
an	NULL
appreciable	NULL
increase	NULL
in	NULL
CD38	NULL
levels	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
induction	NULL
of	NULL
CD38	NULL
is	NULL
a	NULL
specific	NULL
response	NULL
of	NULL
HL-60	NULL
cells	NULL
to	NULL
ATRA	NULL
rather	NULL
than	NULL
a	NULL
general	NULL
response	NULL
of	NULL
cells	NULL
to	NULL
differentiation	NULL
.	NULL

A	NULL
similar	NULL
specificity	NULL
has	NULL
been	NULL
reported	NULL
for	NULL
induction	NULL
of	NULL
2	NULL
other	NULL
enzyme	NULL
proteins	NULL
,	NULL
transglutaminase	NULL
(	NULL
36	NULL
)	NULL
and	NULL
NAD	NULL
*-glycohydrolase	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
NAD	NULL
*-glycohydrolase	NULL
activity	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
encoded	NULL
by	NULL
CD38	NULL
in	NULL
HL-60	NULL
cells	NULL
and	NULL
was	NULL
specifically	NULL
induced	NULL
by	NULL
ATRA	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Contrary	NULL
to	NULL
this	NULL
,	NULL
suppression	NULL
of	NULL
oncogene	NULL
expression	NULL
does	NULL
not	NULL
share	NULL
this	NULL
specific-ity	NULL
;	NULL
both	NULL
ATRA	NULL
and	NULL
DMSO	NULL
treatment	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
the	NULL
mye	NULL
expression	NULL
in	NULL
HL-60	NULL
cells	NULL
(	NULL
38	NULL
)	NULL
.	NULL

It	NULL
would	NULL
appear	NULL
that	NULL
induction	NULL
of	NULL
certain	NULL
enzymes	NULL
such	NULL
as	NULL
transglutaminase	NULL
and	NULL
NAD	NULL
*	NULL
-glycohydrolase	NULL
and	NULL
of	NULL
CD38	NULL
antigen	NULL
may	NULL
be	NULL
selective	NULL
responses	NULL
of	NULL
cells	NULL
to	NULL
retinoids	NULL
,	NULL
whereas	NULL
alteration	NULL
in	NULL
oncogene	NULL
expression	NULL
may	NULL
be	NULL
a	NULL
more	NULL
generalized	NULL
consequence	NULL
of	NULL
retinoid-induced	NULL
differentiation	NULL
.	NULL

Another	NULL
striking	NULL
feature	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
myeloid	NULL
cells	NULL
was	NULL
their	NULL
sensitivity	NULL
to	NULL
ATRA	NULL
doses	NULL
at	NULL
which	NULL
alterations	NULL
in	NULL
the	NULL
level	NULL
of	NULL
this	NULL
antigen	NULL
are	NULL
detected	NULL
;	NULL
fm	NULL
concentrations	NULL
of	NULL
ATRA	NULL
,	NULL
which	NULL
are	NULL
well	NULL
below	NULL
the	NULL
physiological	NULL
level	NULL
(	NULL
1-10	NULL
nm	NULL
)	NULL
,	NULL
can	NULL
induce	NULL
significant	NULL
increases	NULL
in	NULL
CD38	NULL
expression	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
CD38-positive	NULL
cells	NULL
in	NULL
freshly	NULL
isolated	NULL
bone	NULL
marrow	NULL
and	NULL
blood	NULL
cells	NULL
may	NULL
thus	NULL
be	NULL
due	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
CD38	NULL
molecules	NULL
by	NULL
endogenous	NULL
retinoic	NULL
acid	NULL
.	NULL

The	NULL
basal	NULL
level	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
wild	NULL
type	NULL
HL-60	NULL
cells	NULL
is	NULL
much	NULL
higher	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
11.4	NULL
+	NULL
3.2	NULL
)	NULL
than	NULL
in	NULL
HL-6OR	NULL
cells	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
1.2	NULL
+	NULL
0.4	NULL
)	NULL
that	NULL
harbors	NULL
the	NULL
RARa	NULL
with	NULL
decreased	NULL
affinity	NULL
for	NULL
ATRA	NULL
.	NULL

This	NULL
observation	NULL
may	NULL
imply	NULL
that	NULL
endogenous	NULL
retinoids	NULL
present	NULL
in	NULL
serum	NULL
(	NULL
in	NULL
which	NULL
the	NULL
cells	NULL
were	NULL
grown	NULL
)	NULL
may	NULL
be	NULL
enough	NULL
to	NULL
trigger	NULL
high	NULL
levels	NULL
of	NULL
CD38	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
functional	NULL
RARa	NULL
«	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
APL	NULL
cells	NULL
containing	NULL
t	NULL
(	NULL
15:17	NULL
)	NULL
translocation	NULL
that	NULL
involves	NULL
a	NULL
break	NULL
in	NULL
chromosome	NULL
17	NULL
within	NULL
RARa	NULL
gene	NULL
(	NULL
39	NULL
)	NULL
was	NULL
much	NULL
lower	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
2.55	NULL
+	NULL
1.46	NULL
)	NULL
than	NULL
in	NULL
AML	NULL
cells	NULL
(	NULL
S/N	NULL
ratio	NULL
,	NULL
34.1	NULL
+	NULL
21.7	NULL
)	NULL
containing	NULL
functional	NULL
RARa	NULL
(	NULL
34	NULL
)	NULL
further	NULL
supported	NULL
this	NULL
premise	NULL
.	NULL

Little	NULL
information	NULL
is	NULL
available	NULL
on	NULL
the	NULL
possible	NULL
functions	NULL
CD38	NULL
may	NULL
play	NULL
in	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Studies	NULL
with	NULL
an	NULL
1751	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

RAR-a-MEDIATED	NULL
CD38	NULL
EXPRESSION	NULL
IN	NULL
MYELOID	NULL
CELLS	NULL
agonistic	NULL
CD38	NULL
monoclonal	NULL
antibody	NULL
indicated	NULL
that	NULL
T-lymphocytes	NULL
can	NULL
be	NULL
activated	NULL
via	NULL
a	NULL
CD38-mediated	NULL
pathway	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
CD2	NULL
and	NULL
CD3	NULL
(	NULL
40	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
CD38	NULL
may	NULL
function	NULL
as	NULL
a	NULL
receptor	NULL
for	NULL
a	NULL
yet	NULL
unidentified	NULL
ligand	NULL
.	NULL

Recently	NULL
,	NULL
another	NULL
intriguing	NULL
observation	NULL
was	NULL
reported	NULL
by	NULL
States	NULL
et	NULL
al	NULL
.	NULL

(	NULL
41	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
complementary	NULL
DNAs	NULL
encoding	NULL
human	NULL
CD38	NULL
and	NULL
ADP-ribosyl	NULL
cyclase	NULL
,	NULL
an	NULL
enzyme	NULL
originally	NULL
isolated	NULL
from	NULL
Aplysia	NULL
californica	NULL
,	NULL
revealed	NULL
a	NULL
high	NULL
sequence	NULL
identity	NULL
between	NULL
these	NULL
2	NULL
proteins	NULL
.	NULL

ADP-bibosyl	NULL
cyclase	NULL
catalyzes	NULL
the	NULL
synthesis	NULL
of	NULL
cyclic	NULL
ADP-ribose	NULL
,	NULL
a	NULL
metabolite	NULL
of	NULL
NAD	NULL
*	NULL
with	NULL
calcium-mobilizing	NULL
activity	NULL
independent	NULL
of	NULL
inositol-triphosphate	NULL
(	NULL
42	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
Howard	NULL
et	NULL
al	NULL
.	NULL

(	NULL
43	NULL
)	NULL
demonstrated	NULL
that	NULL
purified	NULL
CD38	NULL
could	NULL
catalyze	NULL
the	NULL
formation	NULL
as	NULL
well	NULL
as	NULL
hydrolysis	NULL
of	NULL
cyclic	NULL
ADP-ribose	NULL
.	NULL

These	NULL
observations	NULL
may	NULL
suggest	NULL
that	NULL
CD38	NULL
is	NULL
a	NULL
part	NULL
of	NULL
a	NULL
yet-unknown	NULL
signal	NULL
transduction	NULL
pathway	NULL
that	NULL
might	NULL
be	NULL
responsible	NULL
for	NULL
mediating	NULL
the	NULL
cellular	NULL
response	NULL
to	NULL
an	NULL
extrinsic	NULL
signal	NULL
.	NULL

Further	NULL
experimentation	NULL
is	NULL
needed	NULL
to	NULL
clarify	NULL
these	NULL
possibilities	NULL
and	NULL
to	NULL
determine	NULL
the	NULL
significance	NULL
of	NULL
CD38	NULL
expression	NULL
in	NULL
ATRA-mediated	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
Kung	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
Goldstein	NULL
,	NULL
G.	NULL
,	NULL
Levey	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
Schlossmann	NULL
,	NULL
S.	NULL
F.	NULL
Discrete	NULL
stages	NULL
of	NULL
human	NULL
intrathymic	NULL
differentiation	NULL
:	NULL
analysis	NULL
of	NULL
normal	NULL
thymocytes	NULL
and	NULL
leukemic	NULL
lymphoblasts	NULL
of	NULL
T-cell	NULL
lineage	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
:	NULL
1588-1592	NULL
,	NULL
1980	NULL
.	NULL

2	NULL
.	NULL

Janossy	NULL
,	NULL
G.	NULL
,	NULL
Tidman	NULL
,	NULL
N.	NULL
,	NULL
Papageorgiu	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Kung	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
and	NULL
Goldstein	NULL
,	NULL
G.	NULL
Distribution	NULL
of	NULL
T-lymphocyte	NULL
subsets	NULL
in	NULL
the	NULL
human	NULL
bone	NULL
marrow	NULL
and	NULL
thymus	NULL
:	NULL
an	NULL
analysis	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
726	NULL
:	NULL
1608-1613	NULL
,	NULL
1981	NULL
.	NULL

3	NULL
.	NULL

Holter	NULL
,	NULL
W.	NULL
,	NULL
Majdic	NULL
,	NULL
O.	NULL
,	NULL
Liszka	NULL
,	NULL
K.	NULL
,	NULL
Stockinger	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Knapp	NULL
,	NULL
W.	NULL
Kinetics	NULL
of	NULL
activation	NULL
antigen	NULL
expression	NULL
by	NULL
in	NULL
vifro	NULL
stimulated	NULL
human	NULL
T-lymphocytes	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
90	NULL
:	NULL
322-330	NULL
,	NULL
1985	NULL
.	NULL

4	NULL
.	NULL

Stashenko	NULL
,	NULL
P.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Hardy	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Schlossmann	NULL
,	NULL
S.	NULL
F.	NULL
Expression	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
after	NULL
human	NULL
B	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
78	NULL
:	NULL
3848-3852	NULL
,	NULL
1981	NULL
.	NULL

5	NULL
.	NULL

Bhan	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Stashenko	NULL
,	NULL
P.	NULL
,	NULL
McCluskey	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
and	NULL
Schlossmann	NULL
,	NULL
S.	NULL
F.	NULL
Stages	NULL
of	NULL
B-cell	NULL
differentiation	NULL
in	NULL
human	NULL
lymphoid	NULL
tissue	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
154	NULL
:	NULL
737-743	NULL
,	NULL
1981	NULL
.	NULL

6	NULL
.	NULL

Terstappen	NULL
,	NULL
L.	NULL
W.	NULL
M.	NULL
M.	NULL
,	NULL
Johnsen	NULL
,	NULL
S.	NULL
,	NULL
Segers-Nolten	NULL
,	NULL
I.	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Loken	NULL
M.	NULL
R.	NULL
Identification	NULL
and	NULL
characterization	NULL
of	NULL
plasma	NULL
cells	NULL
in	NULL
normal	NULL
human	NULL
bone	NULL
marrow	NULL
by	NULL
high-resolution	NULL
flow	NULL
cytometry	NULL
.	NULL

Blood	NULL
,	NULL
76	NULL
:	NULL
1739-1747	NULL
,	NULL
1990	NULL
.	NULL

7	NULL
.	NULL

Sieff	NULL
,	NULL
C.	NULL
,	NULL
Bicknell	NULL
,	NULL
D.	NULL
,	NULL
Calne	NULL
,	NULL
G.	NULL
,	NULL
Robinson	NULL
,	NULL
J.	NULL
,	NULL
Lam	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Greaves	NULL
,	NULL
M.	NULL
F.	NULL
Chang	NULL
in	NULL
cell	NULL
surface	NULL
antigen	NULL
expression	NULL
during	NULL
hemopoictic	NULL
differentiation	NULL
.	NULL

Blood	NULL
,	NULL
60	NULL
:	NULL
703-713	NULL
,	NULL
1982	NULL
.	NULL

8	NULL
.	NULL

Terstappen	NULL
,	NULL
L.	NULL
W.	NULL
M.	NULL
M.	NULL
,	NULL
Huang	NULL
,	NULL
S.	NULL
,	NULL
Safford	NULL
,	NULL
M.	NULL
,	NULL
Lansdorp	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
and	NULL
Loken	NULL
,	NULL
M.	NULL
R.	NULL
Sequential	NULL
generation	NULL
of	NULL
hematopoictic	NULL
colonies	NULL
derived	NULL
from	NULL
single	NULL
nonlineage-committed	NULL
CD34+/CD38-progenitor	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
77	NULL
:	NULL
1218-1227	NULL
,	NULL
1991	NULL
.	NULL

9	NULL
.	NULL

Terstappen	NULL
,	NULL
L.	NULL
W.	NULL
M.	NULL
M.	NULL
,	NULL
Safford	NULL
,	NULL
M.	NULL
,	NULL
Unterhalt	NULL
,	NULL
M.	NULL
,	NULL
Koenemann	NULL
,	NULL
S.	NULL
,	NULL
Zurlutter	NULL
,	NULL
K.	NULL
,	NULL
Piechotka	NULL
,	NULL
K.	NULL
,	NULL
Drescher	NULL
,	NULL
M.	NULL
,	NULL
Aul	NULL
,	NULL
C.	NULL
,	NULL
Buechner	NULL
,	NULL
T.	NULL
,	NULL
Hiddemann	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Woermann	NULL
B	NULL
.	NULL

Flow	NULL
cytometric	NULL
characterization	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
:	NULL
IV	NULL
.	NULL

Comparison	NULL
to	NULL
the	NULL
differentiation	NULL
pathway	NULL
of	NULL
normal	NULL
progenitor	NULL
cells	NULL
.	NULL

Leukemia	NULL
,	NULL
6	NULL
:	NULL
993-1000	NULL
,	NULL
1992	NULL
.	NULL

10	NULL
.	NULL

Sporn	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
and	NULL
Roberts	NULL
,	NULL
A.	NULL
S.	NULL
Role	NULL
of	NULL
retinoids	NULL
in	NULL
differentiation	NULL
and	NULL
carcinogen-esis	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
43	NULL
:	NULL
3034-3040	NULL
,	NULL
1983	NULL
.	NULL

11	NULL
.	NULL

Lotan	NULL
,	NULL
R.	NULL
Effects	NULL
of	NULL
vitamin	NULL
A	NULL
and	NULL
its	NULL
analogs	NULL
on	NULL
normal	NULL
and	NULL
neoplastic	NULL
cells	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
605	NULL
:	NULL
33-91	NULL
,	NULL
1980	NULL
.	NULL

12	NULL
.	NULL

Tabin	NULL
,	NULL
C.	NULL
J.	NULL
Retinoids	NULL
,	NULL
homeoboxes	NULL
,	NULL
and	NULL
growth	NULL
factors	NULL
:	NULL
toward	NULL
molecular	NULL
models	NULL
for	NULL
limb	NULL
development	NULL
.	NULL

Cell	NULL
,	NULL
66	NULL
:	NULL
199-217	NULL
,	NULL
1991	NULL
.	NULL

13	NULL
.	NULL

Dennert	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Lotan	NULL
,	NULL
R.	NULL
Effects	NULL
of	NULL
retinoic	NULL
acid	NULL
on	NULL
the	NULL
immune	NULL
system	NULL
:	NULL
stimulation	NULL
of	NULL
T	NULL
killer	NULL
cell	NULL
induction	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
8	NULL
:	NULL
23-29	NULL
,	NULL
1978	NULL
.	NULL

14	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Parkinson	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Cheson	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
and	NULL
Friedman	NULL
,	NULL
M.	NULL
A.	NULL
Retinoids	NULL
in	NULL
cancer	NULL
therapy	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
10	NULL
:	NULL
839-864	NULL
,	NULL
1992	NULL
.	NULL

15	NULL
.	NULL

Breitman	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
Selonick	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
:	NULL
2936-2940	NULL
,	NULL
1980	NULL
.	NULL

16	NULL
.	NULL

Huang	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Ye	NULL
,	NULL
Y.	NULL
C.	NULL
,	NULL
Chen	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Chai	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Lu	NULL
,	NULL
J.	NULL
X.	NULL
,	NULL
Zhoa	NULL
,	NULL
L.	NULL
,	NULL
Gu	NULL
,	NULL
H.	NULL
T.	NULL
,	NULL
and	NULL
Wang	NULL
,	NULL
Z.	NULL
Y	NULL
.	NULL

Use	NULL
of	NULL
all	NULL
trans-retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
,	NULL
72	NULL
:	NULL
567-572	NULL
,	NULL
1988	NULL
.	NULL

17	NULL
.	NULL

Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Ballerini	NULL
,	NULL
P.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
Fenaux	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Degos	NULL
,	NULL
L.	NULL
All	NULL
trans-retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

T.	NULL
Clinical	NULL
results	NULL
.	NULL

Blood	NULL
,	NULL
76	NULL
:	NULL
1704-1709	NULL
,	NULL
1990	NULL
.	NULL

18	NULL
.	NULL

Warrell	NULL
,	NULL
R.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
,	NULL
Scheinberg	NULL
,	NULL
D.	NULL
,	NULL
Itri	NULL
,	NULL
L.	NULL
,	NULL
Hittelman	NULL
,	NULL
W.	NULL
,	NULL
Vyas	NULL
,	NULL
R.	NULL
,	NULL
Andreeff	NULL
,	NULL
M.	NULL
,	NULL
Tafuri	NULL
,	NULL
A.	NULL
,	NULL
Jakubowski	NULL
,	NULL
A.	NULL
,	NULL
Gabrilove	NULL
,	NULL
J.	NULL
,	NULL
Gordon	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Dmitrovsky	NULL
19	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

1752	NULL
E.	NULL
Differentiation	NULL
therapy	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
with	NULL
tretinoin	NULL
(	NULL
all	NULL
trans-retinoic	NULL
acid	NULL
)	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
324	NULL
:	NULL
1385-1393	NULL
,	NULL
1991	NULL
.	NULL

Petkovich	NULL
,	NULL
M.	NULL
,	NULL
Brand	NULL
,	NULL
M.	NULL
,	NULL
Krust	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Chambon	NULL
,	NULL
P.	NULL
A	NULL
human	NULL
retinoic	NULL
receptor	NULL
which	NULL
belongs	NULL
to	NULL
the	NULL
family	NULL
of	NULL
nuclear	NULL
receptors	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
330	NULL
:	NULL
444-450	NULL
,	NULL
1987.	NULL
.	NULL

Benbrook	NULL
,	NULL
D.	NULL
,	NULL
Letnhardt	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Pfahl	NULL
,	NULL
M.	NULL
A	NULL
new	NULL
retinoic	NULL
acid	NULL
receptor	NULL
identified	NULL
from	NULL
a	NULL
hepatocellular	NULL
carcinoma	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
333	NULL
:	NULL
669-672	NULL
,	NULL
1988	NULL
.	NULL

Krust	NULL
,	NULL
A.	NULL
,	NULL
Kastner	NULL
,	NULL
P.	NULL
,	NULL
Petkovich	NULL
,	NULL
M.	NULL
,	NULL
Zelent	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Chambon	NULL
,	NULL
P.	NULL
A	NULL
third	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
,	NULL
hRAR-y	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
:	NULL
5310-5314	NULL
,	NULL
1989	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Ong	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Dyck	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
Nuclear	NULL
receptor	NULL
that	NULL
identifies	NULL
a	NULL
novel	NULL
retinoic	NULL
acid	NULL
response	NULL
pathway	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
345	NULL
:	NULL
224-229	NULL
,	NULL
1990.	NULL
.	NULL

Drach	NULL
,	NULL
J.	NULL
,	NULL
Zhao	NULL
,	NULL
S.	NULL
,	NULL
Malavasi	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Mehta	NULL
,	NULL
K.	NULL
Rapid	NULL
induction	NULL
of	NULL
CD38	NULL
antigen	NULL
on	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
by	NULL
all	NULL
frans-retinoic	NULL
acid	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
195	NULL
;	NULL
545-550	NULL
,	NULL
1993.	NULL
.	NULL

Kontani	NULL
,	NULL
K.	NULL
,	NULL
Nishina	NULL
,	NULL
H.	NULL
,	NULL
Ohoka	NULL
,	NULL
Y.	NULL
,	NULL
Takahashi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Katada	NULL
,	NULL
T.	NULL
NAD	NULL
glycohy-	NULL
drolase	NULL
specifically	NULL
induced	NULL
by	NULL
retinoic	NULL
acid	NULL
in	NULL
human	NULL
leukemic	NULL
HL-60	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
268	NULL
:	NULL
16895-16898	NULL
,	NULL
1993.	NULL
.	NULL

Robertson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Emami	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J.	NULL
Retinoic	NULL
acid-resistant	NULL
HL-60R	NULL
cells	NULL
harbor	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
ligand-binding	NULL
domain	NULL
that	NULL
confers	NULL
dominant	NULL
negative	NULL
activity	NULL
.	NULL

Blood	NULL
,	NULL
80	NULL
:	NULL
1885-1889	NULL
,	NULL
1992	NULL
.	NULL

Robertson	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Emami	NULL
,	NULL
B.	NULL
,	NULL
Mueller	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Multiple	NULL
members	NULL
of	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
family	NULL
are	NULL
capable	NULL
of	NULL
mediating	NULL
the	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
:	NULL
3743-3749	NULL
,	NULL
1992	NULL
.	NULL

Bennett	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Catovsky	NULL
,	NULL
D.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Flandrin	NULL
,	NULL
G.	NULL
,	NULL
Galton	NULL
,	NULL
D.	NULL
A.	NULL
G.	NULL
,	NULL
Grainick	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
and	NULL
Sultan	NULL
,	NULL
C.	NULL
Proposals	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
acute	NULL
leukemia	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
33	NULL
:	NULL
451-455	NULL
,	NULL
1976.	NULL
.	NULL

Drach	NULL
,	NULL
J.	NULL
,	NULL
Lopez-Berestein	NULL
,	NULL
G.	NULL
,	NULL
McQueen	NULL
,	NULL
T.	NULL
,	NULL
Andreeff	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Mehta	NULL
,	NULL
K.	NULL
Induction	NULL
of	NULL
differentiation	NULL
in	NULL
myeloid	NULL
leukemia	NULL
cell	NULL
lines	NULL
and	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
by	NULL
liposomal	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
53	NULL
:	NULL
2100-2104	NULL
,	NULL
1993	NULL
.	NULL

Rizzino	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crowley	NULL
,	NULL
C.	NULL
Growth	NULL
and	NULL
differentiation	NULL
of	NULL
embryonal	NULL
carcinoma	NULL
cell	NULL
line	NULL
Fo	NULL
in	NULL
defined	NULL
media	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
:	NULL
457-461	NULL
,	NULL
1980.	NULL
.	NULL

Olson	NULL
,	NULL
I.	NULL
L.	NULL
,	NULL
and	NULL
Brietman	NULL
,	NULL
T.	NULL
R.	NULL
Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
histiocytic	NULL
lymphoma	NULL
cell	NULL
line	NULL
U-937	NULL
by	NULL
retinoic	NULL
acid	NULL
and	NULL
cyclic-adenosine	NULL
3':5'-monophosphate	NULL
inducing	NULL
agents	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
42	NULL
:	NULL
3924-3927	NULL
,	NULL
1982	NULL
.	NULL

Darmon	NULL
,	NULL
M.	NULL
,	NULL
Rocher	NULL
,	NULL
M.	NULL
,	NULL
Cavey	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Martin	NULL
,	NULL
B.	NULL
,	NULL
Rabilloud	NULL
,	NULL
T.	NULL
,	NULL
Delescluse	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Shroot	NULL
,	NULL
B	NULL
.	NULL

Biological	NULL
activity	NULL
of	NULL
retinoids	NULL
correlates	NULL
with	NULL
affinity	NULL
for	NULL
nuclear	NULL
receptors	NULL
but	NULL
not	NULL
for	NULL
cytosolic	NULL
binding	NULL
protein	NULL
.	NULL

Skin	NULL
Pharmacol	NULL
.	NULL

,	NULL
7	NULL
:	NULL
161-167	NULL
,	NULL
1988	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Robertson	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Mueller	NULL
L-M.	NULL
Retinoic	NULL
acid-induced	NULL
granulocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
is	NULL
mediated	NULL
directly	NULL
through	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
;	NULL
2154-2163	NULL
,	NULL
1990	NULL
.	NULL

Robertson	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Muelier	NULL
,	NULL
L-M.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J.	NULL
Retinoic	NULL
receptors	NULL
in	NULL
myeloid	NULL
leukemia	NULL
:	NULL
characterization	NULL
of	NULL
receptors	NULL
in	NULL
retinoic-acid	NULL
resistant	NULL
K-562	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
77	NULL
:	NULL
340-347	NULL
,	NULL
1991.	NULL
.	NULL

Gallagher	NULL
,	NULL
R.	NULL
,	NULL
Said	NULL
,	NULL
F.	NULL
,	NULL
Pua	NULL
,	NULL
I.	NULL
,	NULL
Papenhausen	NULL
,	NULL
P.	NULL
,	NULL
Paictta	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Wierik	NULL
,	NULL
P.	NULL
Expres-	NULL
sion	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor-a	NULL
in	NULL
human	NULL
leukemia	NULL
cells	NULL
with	NULL
variable	NULL
responsiveness	NULL
to	NULL
retinoic	NULL
acid	NULL
.	NULL

Leukemia	NULL
,	NULL
3	NULL
:	NULL
789-795	NULL
,	NULL
1989	NULL
.	NULL

Parwaresch	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Radzun	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Bodewadt	NULL
,	NULL
S.	NULL
,	NULL
Frendel	NULL
,	NULL
A.	NULL
,	NULL
Sundstrom	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Lennert	NULL
,	NULL
K.	NULL
Alternative	NULL
myelomonocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
reflects	NULL
dual	NULL
prospective	NULL
potency	NULL
of	NULL
promyelocytes	NULL
in	NULL
human	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
89	NULL
:	NULL
385-398	NULL
,	NULL
1984	NULL
.	NULL

Davies	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Murtaugh	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Moore	NULL
,	NULL
W.	NULL
T.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
and	NULL
Lucas	NULL
,	NULL
D.	NULL
Retinoic	NULL
acid-induced	NULL
expression	NULL
of	NULL
tissue	NULL
transglutaminase	NULL
in	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
HL-60	NULL
)	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
260	NULL
:	NULL
5166-5174	NULL
,	NULL
1985	NULL
.	NULL

Hemmi	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Breitman	NULL
,	NULL
T.	NULL
R.	NULL
Induction	NULL
by	NULL
retinoic	NULL
acid	NULL
of	NULL
NAD	NULL
*	NULL
-glycohydrolase	NULL
activity	NULL
of	NULL
myelomonocytic	NULL
cell	NULL
lines	NULL
HL-60	NULL
,	NULL
THP-1	NULL
and	NULL
U-937	NULL
,	NULL
and	NULL
fresh	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
in	NULL
primary	NULL
cultures	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
109	NULL
:	NULL
669-674	NULL
,	NULL
1982	NULL
.	NULL

Westin	NULL
,	NULL
E.	NULL
,	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
,	NULL
Gelmann	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Favera	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Papas	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
Lautenberg	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Eva	NULL
,	NULL
A.	NULL
,	NULL
Reddy	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Tronick	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Aaronson	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
Expression	NULL
of	NULL
cellular	NULL
homologues	NULL
of	NULL
retoviral	NULL
Onc	NULL
genes	NULL
in	NULL
human	NULL
hematopoictic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
79	NULL
:	NULL
2490-2494	NULL
,	NULL
1982	NULL
.	NULL

De	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

The	NULL
t	NULL
(	NULL
15:17	NULL
)	NULL
translocation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor-a	NULL
gene	NULL
to	NULL
a	NULL
novel	NULL
transcribed	NULL
locus	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
347	NULL
:	NULL
558-561	NULL
,	NULL
1990.	NULL
.	NULL

Funaro	NULL
,	NULL
A.	NULL
,	NULL
Spagnoli	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
Ausiello	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Alessio	NULL
,	NULL
M.	NULL
,	NULL
Roggero	NULL
,	NULL
S.	NULL
,	NULL
Delia	NULL
,	NULL
D.	NULL
,	NULL
Zaccolo	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Malavasi	NULL
,	NULL
F.	NULL
Involvement	NULL
of	NULL
the	NULL
multilineage	NULL
CD38	NULL
molecule	NULL
in	NULL
a	NULL
unique	NULL
pathway	NULL
of	NULL
cell	NULL
activation	NULL
and	NULL
proliferation	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
145	NULL
:	NULL
2390-2396	NULL
,	NULL
1990	NULL
.	NULL

States	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Walseth	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
H.	NULL
C.	NULL
Similarities	NULL
in	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
Aplysia	NULL
ADP	NULL
-ribosyl-cyclase	NULL
and	NULL
human	NULL
lymphocyte	NULL
antigen	NULL
CD38	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
17	NULL
:	NULL
495	NULL
,	NULL
1992	NULL
.	NULL

Galione	NULL
,	NULL
A.	NULL
Cyclic	NULL
ADP-ribose	NULL
:	NULL
a	NULL
new	NULL
way	NULL
to	NULL
control	NULL
calcium	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
259	NULL
:	NULL
325-326	NULL
,	NULL
1993	NULL
.	NULL

Howard	NULL
,	NULL
M.	NULL
,	NULL
Grimaldi	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Bazan	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Lund	NULL
,	NULL
F.	NULL
E.	NULL
,	NULL
Santos-Argumedo	NULL
,	NULL
L.	NULL
,	NULL
Parhouse	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Walseth	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
and	NULL
Lee	NULL
,	NULL
H.	NULL
C.	NULL
Formation	NULL
and	NULL
hydrolysis	NULL
of	NULL
cyclic	NULL
ADP-ribose	NULL
catalyzed	NULL
by	NULL
lymphocyte	NULL
antigen	NULL
CD38	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
262	NULL
:	NULL
1056-1059	NULL
,	NULL
1993	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Retinoic	NULL
Acid-induced	NULL
Expression	NULL
of	NULL
CD38	NULL
Antigen	NULL
in	NULL
Myeloid	NULL
Cells	NULL
Is	NULL
Mediated	NULL
through	NULL
Retinoic	NULL
Acid	NULL
Receptor-	NULL
a	NULL
Johannes	NULL
Drach	NULL
,	NULL
Teresa	NULL
McQueen	NULL
,	NULL
Heike	NULL
Engel	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1994	NULL
;	NULL
54:1746-1752	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/54/7/1	NULL
746	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/54/7/1	NULL
746	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

